[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 135
1. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer; 2006 Apr 1;106(7):1624-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic patterns in adenocarcinoma.
  • BACKGROUND: Unique metastatic patterns cited in the literature often arise from anecdotal clinical observations and autopsy reports.
  • The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.
  • METHODS: Tumor registry data were collected between 1994-1996 on 11 primary tumor sites and 15 metastatic sites from 4399 patients.
  • The primary and metastatic sites were cross-tabulated in various ways to identify patterns, and the authors developed algorithms by using multinomial logistic regression analysis to predict the locations of primary tumors based on metastatic patterns.
  • RESULTS: Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91%), prostate to bone (90%), and pancreas to liver (85%).
  • The liver was the dominant metastatic site for gastrointestinal (GI) primary tumors (71% of patients), whereas bone and lung metastases were noted most frequently in non-GI primary tumors (43% and 29%, respectively).
  • In a study of combinations of liver, abdominal cavity, and bone metastases, 86% of prostate primary tumors had only bone metastases, 80% of ovarian primary tumors had only abdominal cavity metastases, and 74% of pancreas primary tumors had only liver metastases.
  • A single organ was the dominant source of metastases in 7 sites: axillary lymph node from the breast (97%), intestinal lymph node from the colon (84%), thoracic lymph node from the lung (66%), brain from the lung (64%), mediastinal lymph node from the lung (62%), supraclavicular lymph node from the breast (51%), and adrenal gland from the lung (51%).
  • [MeSH-major] Adenocarcinoma / secondary. Algorithms. Neoplasm Metastasis. Registries / statistics & numerical data

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM, Cancer and Leukemia Group B: A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist; 2010;15(12):1310-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
  • BACKGROUND: The Cancer and Leukemia Group B (CALGB) conducted a phase II study evaluating sunitinib in patients with progressive metastatic pancreas adenocarcinoma following prior gemcitabine-based therapy (trial CALGB 80603; ClinicalTrials.gov identifier, NCT00397787).
  • PATIENTS AND METHODS: Patients aged ≥18 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and with progressive pancreas adenocarcinoma following treatment with gemcitabine were eligible.
  • CONCLUSIONS: The study met its primary endpoint; however sunitinib had minimal activity and moderate toxicity in a population of gemcitabine-refractory pancreas adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Indoles / therapeutic use. Pancreatic Neoplasms / drug therapy. Pyrroles / therapeutic use. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):193-8 [19047305.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1439-47 [9849429.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1873-82 [19276273.001]
  • [Cites] Oncology. 2009;76(4):254-61 [19246950.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] Curr Drug Metab. 2009 Jun;10(5):470-81 [19689244.001]
  • [Cites] J Gastrointest Cancer. 2009;40(1-2):1-9 [19513861.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1473-85 [19828009.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1487-97 [19828010.001]
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3617-22 [20606091.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7 [20130876.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:69-73 [10436789.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Dec;5(12):1329-39 [15648955.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):369-75 [16012797.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):114-20 [17272317.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4787-92 [17947726.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):463-7 [18202421.001]
  • [Cites] BMC Cancer. 2008;8:82 [18373843.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8 [18172650.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2046-52 [18756532.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):159-66; discussion 166 [11992800.001]
  • (PMID = 21148613.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00397787
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / U10 CA086726; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA045389; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / U10 CA077597; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / U10 CA045418; United States / NCI NIH HHS / CA / CA86726; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / U10 CA047642; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib
  • [Other-IDs] NLM/ PMC3227926
  •  go-up   go-down


3. Yang S, Su J, Cao J, Zhang P, Lu J, Xie W: [Establishment of a Novel Chinese Human Lung Adenocarcinoma Cell Line CPA-Yang1 which Produces Highly Bone Metastases in Immunodeficient Mice.]. Zhongguo Fei Ai Za Zhi; 2009 Jul 20;12(7):753-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of a Novel Chinese Human Lung Adenocarcinoma Cell Line CPA-Yang1 which Produces Highly Bone Metastases in Immunodeficient Mice.].
  • BACKGROUND: Lung cancer is a common malignancy and is the major determinant of overall cancer mortality worldwidely.
  • Approximately 70% of lung cancer patients will die from metastatic diseases.
  • The aim of this study is to establish a Chinese lung adenocarcinoma cell line with high metastasis potency for exploring the mechanism of occurrence and development in lung cancer.
  • METHODS: The cell came from the pericardial effusion of a fifty-year old male patient with lung adenocarcinoma and the cells in primary culture were obtained successfully.
  • The bone metastasis rate was 90% in the tumor bearing mice by bone scintigraphy and pathology and only pulmonary metastasis 10% at the same time.
  • Quantitative real-time PCR was used to examined and compared SPC-A-1 lung adenocarcinoma, VEGF-C, IL-6, IL-8, genes were overexpressed.
  • CONCLUSIONS: Tne novel strain CPA-Yang1 is an parental cell with characteristics of bone metastasis of Chinese lung adenocarcinoma.
  • It has stable traits, highly metastatic ability and a good experimental model for lung cancer research.


Advertisement
4. Maki RG: Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol; 2010 Nov 20;28(33):4985-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulin-like growth factors were discovered more than 50 years ago as mediators of growth hormone that effect growth and differentiation of bone and skeletal muscle.
  • Recent developments regarding phase I to II clinical trials of such agents are discussed, as well as potential studies to consider in the future, given the lack of efficacy of one such monoclonal antibody in combination with cytotoxic chemotherapy in a first-line study in metastatic non-small-cell lung adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 2010 Feb;162(2):249-57 [19917654.001]
  • [Cites] Sci Signal. 2010;3(108):ra10 [20145208.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):327-35 [19337828.001]
  • [Cites] Cell. 2010 Apr 2;141(1):69-80 [20371346.001]
  • [Cites] Mol Cancer Ther. 2010 May;9(5):1286-97 [20457621.001]
  • [Cites] J Pathol. 2010 Jul;221(3):300-7 [20527023.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11122-7 [20534466.001]
  • [Cites] Cancer Res. 2010 Aug 15;70(16):6412-9 [20710042.001]
  • [Cites] Clin Cancer Res. 2010 Sep 15;16(18):4654-65 [20670944.001]
  • [Cites] Cell Res. 2001 Jun;11(2):107-15 [11453542.001]
  • [Cites] Growth Horm IGF Res. 2001 Oct;11(5):289-97 [11735247.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2941-7 [11753970.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7 [11752009.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):454-60 [11904318.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106 [12122101.001]
  • [Cites] J Endocrinol. 2002 Oct;175(1):33-40 [12379488.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6035-8 [12414625.001]
  • [Cites] Nature. 2003 Jan 9;421(6919):182-7 [12483226.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3299-304 [12843179.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):803-8 [14506643.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2211-22 [14657428.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):83-8 [14715249.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):958-60 [15314640.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 27;321(3):524-30 [15358139.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6134-42 [15448000.001]
  • [Cites] Nature. 1976 Dec 9;264(5586):542-5 [1004590.001]
  • [Cites] J Biol Chem. 1978 Apr 25;253(8):2769-76 [632300.001]
  • [Cites] Acta Paediatr Scand Suppl. 1977;(270):15-25 [356516.001]
  • [Cites] FEBS Lett. 1983 Sep 5;161(1):117-21 [6350044.001]
  • [Cites] Am J Gastroenterol. 1985 Apr;80(4):266-9 [3984995.001]
  • [Cites] Annu Rev Physiol. 1985;47:443-67 [2986538.001]
  • [Cites] FEBS Lett. 1985 Sep 9;189(1):115-8 [3896851.001]
  • [Cites] N Engl J Med. 1988 Dec 1;319(22):1434-40 [3185662.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Jan;32(1):65-71 [2331812.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Nov;33(5):593-603 [1701371.001]
  • [Cites] J Clin Invest. 1990 Dec;86(6):1806-14 [2174908.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Aug 30;179(1):579-85 [1715698.001]
  • [Cites] Cancer. 1991 Oct 15;68(8):1673-7 [1913507.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19665-72 [15757893.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1829-33 [16123266.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11118-28 [16322262.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Genes Dev. 2006 Feb 1;20(3):267-75 [16452501.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12743-50 [16517595.001]
  • [Cites] Mutat Res. 2006 Mar 20;595(1-2):117-24 [16448675.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):788-96 [16575403.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40 [16740780.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):597-604 [16827799.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Jul;2(7):395-407 [16932322.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1898-908 [16986125.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):69-74 [16458427.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D237-40 [17135202.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):667-74 [17308062.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1438-44 [17332286.001]
  • [Cites] Growth Horm IGF Res. 2007 Feb;17(1):54-7 [17166755.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):700-6 [17320820.001]
  • [Cites] J Pathol. 2007 Apr;211(5):550-4 [17299733.001]
  • [Cites] BMC Genomics. 2007;8:73 [17359542.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3431-40 [17409454.001]
  • [Cites] Science. 2007 Apr 6;316(5821):112-5 [17412960.001]
  • [Cites] Nat Med. 2007 Jun;13(6):748-53 [17496901.001]
  • [Cites] Arch Biochem Biophys. 2007 Sep 15;465(2):359-69 [17644060.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5834-40 [17908976.001]
  • [Cites] Adv Exp Med Biol. 2007;612:104-18 [18161484.001]
  • [Cites] J Intern Med. 2008 Feb;263(2):179-91 [18226095.001]
  • [Cites] Endocrinology. 2008 Mar;149(3):1214-26 [18039785.001]
  • [Cites] FASEB J. 2008 Mar;22(3):807-18 [17928362.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1538-45 [18316619.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2007;72:483-8 [18419308.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3204-15 [18483389.001]
  • [Cites] Front Biosci. 2008;13:3906-12 [18508484.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92 [18550829.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1293-8 [18372285.001]
  • [Cites] Cell. 1992 Apr 3;69(1):119-28 [1555236.001]
  • [Cites] Nature. 1992 Oct 8;359(6395):554-6 [1406976.001]
  • [Cites] Cell. 1993 Oct 8;75(1):59-72 [8402901.001]
  • [Cites] J Intern Med. 1993 Dec;234(6):543-52 [7505031.001]
  • [Cites] J Endocrinol. 1993 Sep;138(3):545-54 [7506292.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2803-7 [8168113.001]
  • [Cites] Mol Cell Biol. 1994 Jul;14(7):4588-95 [8007963.001]
  • [Cites] EMBO J. 1994 Jul 15;13(14):3286-95 [8045259.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1635-41 [7895674.001]
  • [Cites] J Biol Chem. 1995 Jun 9;270(23):13589-92 [7539790.001]
  • [Cites] Nat Genet. 1995 Jun;10(2):196-201 [7663515.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1545-50 [8603400.001]
  • [Cites] J Biol Chem. 1996 Aug 9;271(32):19304-9 [8702614.001]
  • [Cites] Pediatr Res. 1996 Jun;39(6):992-8 [8725260.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):634-41 [8814167.001]
  • [Cites] J Clin Invest. 1996 Dec 1;98(11):2612-5 [8958225.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 10):S10-3-S10-10 [9275000.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] Lancet. 1998 May 9;351(9113):1393-6 [9593409.001]
  • [Cites] Blood Press. 1998 May;7(2):89-95 [9657535.001]
  • [Cites] Int Rev Cytol. 1998;183:1-94 [9666565.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2383-90 [9796969.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):620-5 [10203281.001]
  • [Cites] J Lab Clin Med. 1957 Jun;49(6):825-36 [13429201.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jan 14;229(1-2):149-60 [15607539.001]
  • [Cites] Endocrinology. 2005 Feb;146(2):851-60 [15498882.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1563-71 [15746061.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3868-76 [15867386.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3196-203 [18474873.001]
  • [Cites] PLoS One. 2008;3(7):e2578 [18596909.001]
  • [Cites] Nature. 2008 Jul 17;454(7202):345-9 [18528331.001]
  • [Cites] Cell. 2008 Aug 8;134(3):405-15 [18674809.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2589-98 [18765823.001]
  • [Cites] J Endocrinol. 2008 Oct;199(1):69-80 [18653623.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8039-48 [18829562.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):3098-103 [18802403.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1860-9 [18641009.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):639-57 [18971124.001]
  • [Cites] J Pathol. 2008 Dec;216(4):428-39 [18855347.001]
  • [Cites] Cancer Cell. 2008 Dec 9;14(6):447-57 [19061836.001]
  • [Cites] J Pathol. 2009 Mar;217(4):469-82 [19148905.001]
  • [Cites] FEBS J. 2009 Mar;276(5):1221-32 [19175674.001]
  • [Cites] Pediatr Dev Pathol. 2009 Mar-Apr;12(2):127-35 [18788888.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):725-31 [19279572.001]
  • [Cites] Nature. 2009 Apr 23;458(7241):1056-60 [19262508.001]
  • [Cites] Anticancer Res. 2009 Apr;29(4):1131-5 [19414355.001]
  • [Cites] Curr Oncol Rep. 2009 Jul;11(4):307-13 [19508836.001]
  • [Cites] Nat Rev Endocrinol. 2009 Jul;5(7):367-73 [19455179.001]
  • [Cites] Mod Pathol. 2009 Jul;22(7):914-21 [19407853.001]
  • [Cites] Nature. 2009 Jul 16;460(7253):392-5 [19587680.001]
  • [Cites] Semin Oncol. 2009 Aug;36(4):338-46 [19664494.001]
  • [Cites] Science. 2009 Oct 2;326(5949):140-4 [19797661.001]
  • [Cites] Lancet. 2009 Oct 3;374(9696):1196-208 [19801098.001]
  • [Cites] PLoS One. 2009;4(10):e7273 [19806209.001]
  • [Cites] Endocr Regul. 2009 Oct;43(4):149-55 [19908933.001]
  • [Cites] Eur J Hum Genet. 2009 Dec;17(12):1668-75 [19491931.001]
  • [Cites] J Clin Oncol. 2009 Dec 1;27(34):5800-7 [19786654.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1128-33 [10534157.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):1-9 [10699960.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1598-600 [10770203.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1101-7 [11007947.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33607-13 [10874028.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • (PMID = 20975071.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA148260; United States / NCI NIH HHS / CA / RC2 CA148260; United States / NCI NIH HHS / CM / CM62202; United States / NCI NIH HHS / CA / CA47179; United States / NCI NIH HHS / CA / N01CM62202; United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Somatomedins; EC 2.7.10.1 / Receptor, IGF Type 1
  • [Other-IDs] NLM/ PMC3039924
  •  go-up   go-down


5. Charoentum C: Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year. J Med Assoc Thai; 2006 Jun;89(6):882-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year.
  • A 53-year old non-smoking Thai female was diagnosed with metastatic non-small cell lung cancer to bone.
  • The initial biopsy from the bone lesion showed metastatic adenocarcinoma.
  • This result is consistent with previous reports that the clinical characteristics of female, non-smoker and adenocarcinoma histology seem to predict response to gefitinib.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Neoplasm Recurrence, Local / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850692.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


6. Yasar F, Oz G, Dolanmaz D, Akgünlü F: Mandibular metastasis in a patient with pulmonary adenocarcinoma. Dentomaxillofac Radiol; 2006 Sep;35(5):383-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mandibular metastasis in a patient with pulmonary adenocarcinoma.
  • Metastatic tumour spread to the mandible is quite rare.
  • We report a case of distant metastasis of pulmonary adenocarcinoma in the mandibular bone.
  • The patient had pain in his left mandibular premolar-molar area caused by a mandibular metastasis from a previously undiagnosed pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Mandibular Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940489.001).
  • [ISSN] 0250-832X
  • [Journal-full-title] Dento maxillo facial radiology
  • [ISO-abbreviation] Dentomaxillofac Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Tomita A, Kasaoka T, Inui T, Toyoshima M, Nishiyama H, Saiki H, Iguchi H, Nakajima M: Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis. Clin Exp Metastasis; 2008;25(4):437-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis.
  • Osteolysis is an important process in the establishment of bone metastasis.
  • In this study, we first established a reproducible in vivo bone metastasis model using two types of tumor cells, human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara cells), and examined in vitro characteristics of the tumor cells.
  • Tumor cells injected into the left heart ventricle of nude mice preferentially metastasized to bone, 6 weeks after the inoculation.
  • Histological observation of the bone metastatic lesion showed that tumor cells invaded the bone marrow, and osteoclasts adjacent to fibroblasts were actively resorbing the bone matrix.
  • In vitro analysis of the tumor cells showed that MDA-231 cells express cathepsin K, matrix metalloproteinase 9 (MMP-9), and membrane type-1 matrix metalloproteinase (MT1-MMP), all of which are believed to play an important role in osteoclastic bone resorption.
  • Taken together, we conclude that MDA-231 and Hara cells, which metastasize to the bone in vivo, do not have enough ability to achieve bone resorption by themselves, but rather achieve it through activation of fibroblast like cells and osteoclasts.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / secondary. Bone Resorption / etiology. Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):24-7 [11668474.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4451-8 [10499498.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11001-9 [16322249.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):4040-3 [8752176.001]
  • [Cites] Bone Miner. 1992 Jun;17(3):347-59 [1623329.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5802-7 [8242639.001]
  • [Cites] Scan Electron Microsc. 1986;(Pt 4):1537-54 [3544196.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):32347-52 [9822715.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):1106-9 [8288568.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8109-12 [9079619.001]
  • [Cites] J Bone Miner Res. 1998 Jan;13(1):59-66 [9443791.001]
  • [Cites] Life Sci. 2006 Sep 20;79(17):1657-60 [16806280.001]
  • [Cites] Nature. 1994 Jul 7;370(6484):61-5 [8015608.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5849-55 [10582709.001]
  • [Cites] J Cell Sci. 1997 Mar;110 ( Pt 5):589-96 [9092941.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1318-26 [12698202.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13453-8 [9811821.001]
  • [Cites] Lab Invest. 1995 Mar;72(3):311-22 [7898050.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Jul 31;186(2):911-7 [1379809.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jan 5;206(1):89-96 [7818555.001]
  • [Cites] Bone. 1997 Feb;20(2):81-6 [9028530.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 29;258(1):173-8 [10222255.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5571-9 [12359770.001]
  • [Cites] Bone. 2003 Jul;33(1):28-37 [12919697.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):18-24 [11516200.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3551-7 [7627963.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 25;319(2):690-6 [15178461.001]
  • [Cites] Tissue Cell. 2001 Oct;33(5):478-82 [11949783.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2003 Feb;270(2):152-61 [12524690.001]
  • [Cites] J Biol Chem. 1994 May 27;269(21):15006-9 [8195136.001]
  • [Cites] Endocr Rev. 1999 Jun;20(3):345-57 [10368775.001]
  • [Cites] J Biol Chem. 1996 Jan 26;271(4):2126-32 [8567669.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1544-9 [8833902.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12511-6 [8647859.001]
  • [Cites] J Cell Biol. 2000 Nov 13;151(4):879-89 [11076971.001]
  • [Cites] J Biol Chem. 1995 Jan 13;270(2):801-5 [7822314.001]
  • (PMID = 18301992.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 0 / RNA, Messenger; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K; EC 3.4.22.38 / Ctsk protein, mouse; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


8. Kreusel KM, Bechrakis NE, Wiegel T, Krause L, Foerster MH: Incidence and clinical characteristics of symptomatic choroidal metastasis from lung cancer. Acta Ophthalmol; 2008 Aug;86(5):515-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and clinical characteristics of symptomatic choroidal metastasis from lung cancer.
  • PURPOSE: To determine the clinical characteristics of symptomatic choroidal metastasis (CM) resulting from metastatic lung cancer.
  • METHODS: Twenty-two consecutive patients with symptomatic CM resulting from lung cancer were retrospectively reviewed for ocular findings, medical history and systemic disease.
  • All patients underwent a complete screening for further organ metastasis by computed tomography (CT) and bone scintigraphy.
  • RESULTS: In eight of 22 (36%; 95% confidence interval [CI] 17-59) patients, lung cancer had been diagnosed before occurrence of CM, with a median interval of 13 months.
  • In 14 patients lung cancer was detected after diagnosis of CM, with a median interval of 1 month.
  • Median survival after diagnosis of symptomatic CM was 13 months, by contrast with 2 months in lung cancer patients with CM identified in an ocular screening study.
  • CONCLUSIONS: Symptomatic choroidal lung cancer metastasis in the majority of patients presents as a solitary tumour before diagnosis of lung cancer in patients with multiple organ systems affected by metastatic disease.
  • [MeSH-major] Choroid Neoplasms / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Adult. Aged. Carcinoid Tumor / diagnosis. Carcinoid Tumor / epidemiology. Carcinoid Tumor / secondary. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / epidemiology. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / secondary. Female. Humans. Incidence. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Small Cell Lung Carcinoma / diagnosis. Small Cell Lung Carcinoma / epidemiology. Small Cell Lung Carcinoma / secondary. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081901.001).
  • [ISSN] 1755-3768
  • [Journal-full-title] Acta ophthalmologica
  • [ISO-abbreviation] Acta Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, Braverman LE, Busutti L, degli Uberti EC: Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid; 2005 Mar;15(3):267-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven patients had high positive rhTSH Tg testing and (131)I uptake was detected in lung, bone, or mediastinum in 11.
  • Imaging techniques (computed tomography [CT], magnetic resonance imaging [MRI], fluorine-18 2-fluoro-2-deoxy-D-glucose-positron emission tomography [FDGPET]) documented metastatic disease in 22.
  • [MeSH-minor] Adenocarcinoma, Papillary / blood. Adenocarcinoma, Papillary / pathology. Adolescent. Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Positron-Emission Tomography. Recurrence. Reproducibility of Results. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785246.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


10. Destombe C, Botton E, Le Gal G, Roudaut A, Jousse-Joulin S, Devauchelle-Pensec V, Saraux A: Investigations for bone metastasis from an unknown primary. Joint Bone Spine; 2007 Jan;74(1):85-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigations for bone metastasis from an unknown primary.
  • OBJECTIVES: To evaluate the respective contributions of various investigations used to identify the primary tumor in a cohort of patients referred for diagnostic evaluation of one or more bone metastases.
  • METHODS: A single-center retrospective study was conducted in a cohort of patients admitted between October 1990 and January 2000 for evaluation of one or more bone metastases with no known primary.
  • All patients underwent radionuclide bone scanning, a chest radiograph, and an abdominal ultrasound scan.
  • Using the final diagnosis as the reference standard, we evaluated the diagnostic usefulness of each investigation.
  • The primary was located in the lung in 37 patients, prostate in 26, breast or female genital tract in 24, urinary system in 11, gastrointestinal tract in 11, head and neck in 6, and other organs in 4.
  • The extraskeletal metastases were located chiefly in the liver (20.4%), lung (17.1%), pleura (13.2%), and brain (7.2%).
  • Bone biopsies were performed in 107 patients: 84 had a single bone biopsy, 16 had two bone biopsies, and 7 had three bone biopsies.
  • The first bone biopsy was taken in the rheumatology department with or without fluoroscopic guidance in 62 patients, in the radiology department under CT guidance in 6 patients, and in the surgery department in 32 patients; this information was unavailable for the 7 remaining patients.
  • The first bone biopsy was taken from the iliac bone in 48 patients, spine in 32, sacrum in 10, rib in 3, and other sites in 7.
  • The histological biopsy findings indicated adenocarcinoma in 58 cases, epidermoid carcinoma in 28 cases, undifferentiated carcinoma in 2 cases, and other histological patterns in 9 cases.
  • In 80 patients, another metastatic site was easier to access than the bone metastasis.
  • CONCLUSION: Bone biopsies performed by rheumatologists, generally under fluoroscopic guidance, usually indicate the site of the primary or at least the histological type.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Biopsy. Bone and Bones / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Cohort Studies. Diagnostic Imaging. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Joint Bone Spine. 2008 Jan;75(1):100; author reply 100-1 [18083617.001]
  • (PMID = 17218141.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC: Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol; 2009 Oct;4(10):1212-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
  • The correlation of biomarker expression between the primary tumor and its corresponding metastasis has not yet been well documented and analyzed in patients with non-small cell lung cancer (NSCLC).
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Bone Neoplasms / metabolism. Brain Neoplasms / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / metabolism. Survival Rate. Vascular Endothelial Growth Factor A / metabolism


12. David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, Braverman LE, Busutti L, degli Uberti EC: Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid; 2005 Feb;15(2):158-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven patients had high positive rhTSH Tg testing and (131)I uptake was detected in lung, bone, or mediastinum in 11.
  • Imaging techniques (CT, MRI, FDG-PET) documented metastatic disease in 22.
  • [MeSH-minor] Adenocarcinoma, Follicular / radionuclide imaging. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Iodine Radioisotopes. Male. Middle Aged. Neoplasm, Residual / pathology. Neoplasm, Residual / radionuclide imaging. Postoperative Complications / drug therapy. Recombinant Proteins / therapeutic use. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2006 May;16(5):517-9 [16756477.001]
  • (PMID = 15753676.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Recombinant Proteins; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


13. Wang CY, Zhang XY: [(99m)Tc-MDP wholebody bone imaging in evaluation of the characteristics of bone metastasis of primary lung cancer]. Zhonghua Zhong Liu Za Zhi; 2010 May;32(5):382-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [(99m)Tc-MDP wholebody bone imaging in evaluation of the characteristics of bone metastasis of primary lung cancer].
  • OBJECTIVE: To explore the image characteristics of bone metastasis of primary lung carcinoma.
  • METHODS: Whole-body bone imaging ((99)Tc(m)-MDP) was performed in 258 patients with pathologically proven lung carcinoma.
  • The rate of bone metastasis, distribution of the metastatic lesions and their characteristics were analyzed.
  • RESULTS: Among the 258 cases, 142 patients developed bone metastasis.
  • The overall rate of bone metastasis was 55.0%.
  • Ribs, thoracic vertebrae, ilium and lumbar vertebrae had a higher rate of bone metastasis, higher than 20%, respectively.
  • 1224 bone metastatic foci (97.8%) were presented as strong radioactive, 26 (2.1%) mixed lesion, and 2 (0.2%) low radioactive.
  • The accumulative bone metastasis rate was 28.7% for the patients with one to three lesions.
  • The metastasis rate decreased gradually with the increasing number of metastatic lesions.
  • CONCLUSION: Bone metastasis is very common in patients with lung cancer.
  • Most bone metastases are characterized by strong radioactive and earlier punctate form, often occurs in the trunk bones of axial skeleton or appendicular girdles.
  • The distribution of earlier metastases has not obvious regularity, and advanced bone metastases are often concurrent, multiple and multiform, widely and randomly distributed in the body.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Technetium Tc 99m Medronate. Tomography, Emission-Computed, Single-Photon. Whole Body Imaging
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adult. Aged. Aged, 80 and over. Bone and Bones / pathology. Bone and Bones / radionuclide imaging. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Male. Middle Aged. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723439.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate; Adenocarcinoma of lung
  •  go-up   go-down


14. Masutani K, Fujisaki K, Maeda H, Toyonaga J, Inoshima I, Takayama K, Katafuchi R, Hirakata H, Tsuruya K, Iida M: Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. Clin Exp Nephrol; 2008 Oct;12(5):398-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib.
  • Two years prior to admission, she was diagnosed with lung adenocarcinoma and multiple bone and brain metastases, and was treated with gefitinib (250 mg/day).
  • Treatment for 6 months induced partial response with 30% regression of the primary lung tumor, and resolution of metastatic tumors.
  • In consideration of the prognosis of lung cancer and complication of immunosuppressive treatment, we continued gefitinib only and closely followed-up the clinical course in the outpatient clinic.
  • However, the lung cancer started to increase in size.
  • [MeSH-major] Adenocarcinoma / drug therapy. Glomerulonephritis, IGA / chemically induced. Lung Neoplasms / drug therapy. Nephritis, Interstitial / chemically induced. Quinazolines / adverse effects. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2549-56 [16735708.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2240-50 [11980995.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1044-6 [16048398.001]
  • [Cites] Clin Exp Nephrol. 2005 Sep;9(3):262-3 [16189639.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5054-9 [12941834.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):137-9 [12531582.001]
  • [Cites] Kidney Int. 2004 Nov;66(5):1805-14 [15496151.001]
  • [Cites] Am J Physiol. 1988 Dec;255(6 Pt 2):F1191-6 [3264462.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2504-5 [15197213.001]
  • [Cites] Clin Exp Nephrol. 2004 Dec;8(4):297-303 [15619027.001]
  • [Cites] FASEB J. 2004 May;18(7):926-8 [15033924.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2003 Aug;41(8):565-8 [14503345.001]
  • [Cites] Kidney Int. 2003 Nov;64(5):1573-9 [14531789.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17612-8 [10364198.001]
  • (PMID = 18575950.001).
  • [ISSN] 1342-1751
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


15. Yanagitani N, Kaira K, Ishizuka T, Aoki H, Utsugi M, Shimizu Y, Sunaga N, Endou K, Hisada T, Mori M: Multiple lung metastases presenting as ground-glass opacities in a pulmonary adenocarcinoma: a case report. Cases J; 2009;2:6910
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple lung metastases presenting as ground-glass opacities in a pulmonary adenocarcinoma: a case report.
  • INTRODUCTION: Focal ground-glass opacity on computed tomography suggests several disorders including inflammatory disease, fibrosis, or a primary lung neoplastic lesion, metastatic lung tumor.
  • CASE PRESENTATION: The case of a 55-year-old female presenting with adenocarcinoma of the lung is herein reported.
  • Computed tomography of the chest revealed a primary mass lesion in the upper lobe of the right lung and multiple metastases presenting as ground-glass opacities.
  • Macroscopic metastases were observed in the bone, the hilar and mediastinal lymph nodes, and another lobe.
  • This case was advanced lung cancer.
  • CONCLUSION: A metastatic lung tumor showing ground-glass opacity is uncommon.
  • It is quite difficult to distinguish between multiple primary lung cancers and intrapulmonary metastasis when patients present with multiple lung nodules.
  • A lot of clinical information is therefore required to make an accurate diagnosis in such cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):e1-2 [15620900.001]
  • [Cites] Ann Thorac Surg. 2006 Oct;82(4):1508-10 [16996967.001]
  • (PMID = 19829882.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740189
  •  go-up   go-down


16. Nogawa M, Yuasa T, Kimura S, Kuroda J, Sato K, Segawa H, Yokota A, Maekawa T: Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett; 2005 Jan 20;217(2):243-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that the growth and metastases of HT1080 fibrosarcoma, A549 lung adenocarcinoma, and RENCA murine renal cancer cell lines in five different in vivo models can be successfully monitored by labeling the cells with luciferase prior to their implantation and then detecting their bioluminesence after injecting luciferin.
  • We also used this in vivo imaging system to successfully demonstrate that YM529, a third generation bisphosphonate, inhibited the growth of sarcoma metastases in bone.
  • We believe the models we have established in combination with the in vivo imaging system will be highly useful for future studies of metastasis and the testing of anti-metastatic therapies.
  • [MeSH-major] Cell Proliferation. Diagnostic Imaging / methods. Luciferases. Neoplasm Metastasis / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617843.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 127657-42-5 / YM 529; EC 1.13.12.- / Luciferases
  •  go-up   go-down


17. Keramidas E, Brotherston M: Extensive metastasis to the hand from undiagnosed adenocarcinoma of the lung. Scand J Plast Reconstr Surg Hand Surg; 2005;39(2):113-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive metastasis to the hand from undiagnosed adenocarcinoma of the lung.
  • Metastatic tumours of the hand are uncommon; we present a case of undiagnosed adenocarcinoma of the lung with extensive metastases to the carpal, and to the third, fourth, and fifth metacarpal, bones.
  • Biopsy confirmed the diagnosis and the patient died three months later, no surgical treatment being offered.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019740.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Lim C, Chan R, Regan W: Renal cell carcinoma with cutaneous metastases. Australas J Dermatol; 2005 Aug;46(3):158-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Shave biopsies and excisions of the cutaneous lesions revealed findings consistent with metastatic renal cell carcinoma of clear cell type.
  • During this time, metastases to the bone, lung, soft palate and posterior leg were also diagnosed.
  • This case represents an unusual clinical presentation of metastatic renal cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Aged, 80 and over. Ear Neoplasms / diagnosis. Ear Neoplasms / secondary. Ear Neoplasms / therapy. Facial Neoplasms / diagnosis. Facial Neoplasms / secondary. Facial Neoplasms / therapy. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / therapy. Humans. Lip Neoplasms / diagnosis. Lip Neoplasms / secondary. Lip Neoplasms / therapy. Male. Nephrectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008646.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


19. Lasithiotakis K, Petrakis I, Georgiadis G, Paraskakis S, Chalkiadakis G, Chrysos E: Pancreatic resection for metastasis to the pancreas from colon and lung cancer, and osteosarcoma. JOP; 2010;11(6):593-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic resection for metastasis to the pancreas from colon and lung cancer, and osteosarcoma.
  • CONTEXT: Pancreatic resection for a metastatic colon, lung cancer or an osteosarcoma has rarely been reported in the literature and there is controversy regarding recurrence and the overall survival of these patients.
  • We herein evaluate the outcome of three patients who underwent pancreaticoduodenectomy for the aforementioned metastatic tumors to the pancreas.
  • All the pancreatic lesions were located in the head of the pancreas, and the intervals between the diagnosis of the primary cancer and the pancreatic metastases were 6, 14 and 24 months.
  • During exploration of the abdomen, additional metastatic lesions in the small intestine and liver were detected and resected in two patients.
  • CONCLUSION: Pancreatic resection for metastatic disease may be suggested for selected patients, even those with limited extrapancreatic disease.
  • [MeSH-major] Bone Neoplasms / pathology. Colonic Neoplasms / pathology. Lung Neoplasms / pathology. Osteosarcoma / pathology. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Female. Humans. Male. Middle Aged. Pancreatectomy / methods


20. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res; 2005 May-Jun;25(3c):2399-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue.
  • In that series, patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • PATIENTS AND METHODS: Five patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • RESULTS: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Caffeine / pharmacology. Carcinoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080466.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


21. Parvez T, Ibraheim MI: Diagnostic and prognostic yield of tumor markers in cancer of unknown primary site. J Coll Physicians Surg Pak; 2006 Feb;16(2):154-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of metastatic carcinoma of unknown primary is reported that had widely disseminated disease from the very outset.
  • It was assumed that lung was the most possible site for primary.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / blood. Bone Neoplasms / secondary. CA-125 Antigen / blood. Lung Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Humerus. Lumbar Vertebrae. Prognosis. Ribs

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499817.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


22. Husain A, Blumenschein G, Esmaeli B: Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol; 2008 Mar;47(3):276-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.
  • OBJECTIVE: To report the management and outcomes in patients with metastatic eyelid sebaceous cell carcinoma.
  • METHODS: The clinical records of four patients with metastatic eyelid sebaceous cell carcinoma treated between January 1999 and August 2006 were reviewed.
  • Metastatic sites included the lung in three patients, regional lymph nodes in two, liver in two, and bone in one.
  • Time from diagnosis of eyelid carcinoma to metastasis ranged from 0 to 62 months.
  • One patient developed lung metastasis 5 years after the diagnosis of eyelid tumor; she was treated with systemic chemotherapy followed by subtotal lung resection.
  • The follow-up time from diagnosis of metastasis to last contact or death ranged from 1 month to 3 years (median of 21 months).
  • Treatment of metastatic disease may include a combination of chemotherapy, radiation, and surgical neck dissection.
  • [MeSH-major] Adenocarcinoma, Sebaceous / secondary. Bone Neoplasms / secondary. Eyelid Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Parotid Neoplasms / secondary. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Chalazion / diagnosis. Diagnostic Errors. Female. Humans. Lymphatic Metastasis / radiotherapy. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289332.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Hill HC: Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma. J Natl Med Assoc; 2008 Dec;100(12):1469-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma.
  • Treatment is based upon the results of several diagnostic radiographic modalities that may locate the occult primary and determine the extent of metastatic tumor burden.
  • We describe metastatic adenocarcinoma of unknown primary presenting as a pericardial effusion and coincident supraclavicular adenopathy.
  • The patient completed the chemotherapy and had stable metastatic tumor burden with an acceptable quality of life.
  • Two years after initial diagnosis, the patient expired because of disease progression.
  • Although immunohistochemical staining initially suggested metastatic breast carcinoma, her clinical course confirmed a lung primary.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Bromhexine. Fatal Outcome. Female. Humans. Immunohistochemistry. Pericardial Effusion / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Med Assoc. 2009 May;101(5):478 [19476202.001]
  • (PMID = 19110917.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q1J152VB1P / Bromhexine
  •  go-up   go-down


24. Wu Y, Yao LQ, Cheng J, Tian H: [Diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):1069-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site].
  • OBJECTIVE: To explore the diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site.
  • METHODS: Thirty-eight cases of metastatic bone marrow tumors were diagnosed by light microscopy, and the bone marrow samples from these cases with unknown primary tumor sites were examined by immunohistochemistry.
  • RESULTS: In all the cases, the bone marrow was infiltrated by tumor cells between the bone trabecula.
  • Immunohistochemistry identified the primary tumor sites in these cases, including 12 stomach cancers, 10 breast cancers, 8 prostate cancers, 4 lung cancers, 1 dorsal melanoma, 1 left foot melanoma, and 2 nasopharyngeal cancers.
  • CONCLUSION: Proper immunohistochemistry can help determine the primary tumor sites in patients with metastatic bone marrow tumor with unknown primary tumor sites.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Marrow Examination / methods. Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501396.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


25. Li XF, Zanzonico P, Ling CC, O'Donoghue J: Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography. Technol Cancer Res Treat; 2006 Apr;5(2):147-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography.
  • The objective of this study was to evaluate the utility of micro-computed tomography (micro-CT) for the detection and monitoring of experimental lung and bone metastases in nude mice.
  • Whole body micro-CT scans were performed in lung or bone metastasis-bearing nude mice under deep anesthesia.
  • The volumes of individual lung metastases were estimated by micro-CT, and compared to direct measurements on excised tumors.
  • The smallest lung tumor detected was 0.85 mm in diameter.
  • The progression of metastatic lung disease, including tumor growth and the development of pleural effusion, was visualized by serial micro-CT scans in live mice.
  • Bone lesions identified by micro-CT were confirmed as metastases by histopathological examination.
  • Micro-CT may be used as an accurate, noninvasive tool to detect and monitor experimental bone and lung metastases in intact live nude mice.
  • [MeSH-major] Adenocarcinoma / radiography. Bone Neoplasms / radiography. Lung Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551134.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ludwick C, Gilks CB, Miller D, Yaziji H, Clement PB: Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. Int J Gynecol Pathol; 2005 Jul;24(3):205-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical findings supported that they were primary tumors rather than metastatic from an occult primary tumor.
  • On follow-up, each patient experienced recurrent disease 7 months to 4.5 years after diagnosis, including hematogenous spread to lung and/or bone and liver in three patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968194.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


27. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N: Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev; 2008 Dec;34(8):693-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The commonest histologic subtypes encountered were adenocarcinoma (N=34) or undifferentiated carcinoma (N=12).
  • The liver was the only metastatic site in 38% of patients, while it was accompanied with other metastatic sites in 62% (the commonest: lung, bone and lymph nodes).
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584969.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 22
  •  go-up   go-down


28. Cadière GB, Himpens J, Torres R, Dapri G, Bosschaerts T, Karler C, Haller A: Multimedia article. Entirely thoracoscopic pneumonectomy using the prone position: a new technique. Surg Endosc; 2005 Sep;19(9):1282-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 49-year-old man was admitted to our hospital for a bifocal cancer of the left lower lung lobe (LLL) and the cervical esophagus.
  • Biopsy showed invasive adenocarcinoma, and a CT scan of the neck and head was significant for tumoral infiltration of the cervical esophagus and retropharyngeal space.
  • Biopsy showed spinocellular epithelioma, but CT scan of the abdomen and bone scintigraphy did not show metastatic disease.
  • The lung was freed entirely tend placed in a retrieval bag for later transhiatal extraction during the laparoscopic phase of the esophagectomy.
  • The pathology report confirmed the presence of invasive, poorly differentiated adenocarcinoma.
  • Dissection of the hilar larger vessels and performance of lymphnode sampling appear more straightforward because with this technique, the lung is kept out of harm's way, thanks to gravity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Surg. 1996 Oct-Dec;81(4):354-8 [9127794.001]
  • [Cites] Surg Endosc. 1997 Apr;11(4):354-8 [9094276.001]
  • [Cites] Ann Thorac Surg. 2002 Aug;74(2):615-23 [12173869.001]
  • [Cites] Int Surg. 1996 Jul-Sep;81(3):255-8 [9028985.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Dec;126(6):2083-5 [14688732.001]
  • [Cites] Eur J Cardiothorac Surg. 1996;10(3):161-7 [8664015.001]
  • [Cites] J R Coll Surg Edinb. 1992 Feb;37(1):7-11 [1573620.001]
  • [Cites] Int Surg. 2000 Jan-Mar;85(1):6-12 [10817423.001]
  • [Cites] Ann Thorac Surg. 2002 Jan;73(1):240-4 [11834016.001]
  • (PMID = 16249969.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


29. Karacetin D, Yalcin B, Okten B, Ozturk S, Maral O, Incekara O: Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer. J BUON; 2009 Oct-Dec;14(4):605-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
  • These drugs have been found to act synergistically, both in vivo and in vitro and their combination (XELOX) is highly active in metastatic colorectal cancer (mCRC).
  • Patient selection criteria included histological confirmation of mCRC, ECOG performance status (PS) <or=2, and adequate bone marrow, renal and hepatic function.
  • Metastatic sites were the liver (23/34; 67%), lung (7/34; 20%), and bone (4/34; 11%).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy


30. Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK: Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res; 2010 May 1;70(9):3494-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
  • The tropism of breast cancer cells for bone and their tendency to induce an osteolytic phenotype are a result of interactions between breast cancer cells and stromal cells and are of paramount importance for bone metastasis.
  • We hypothesize that tumor-stromal interaction alters gene expression in malignant tumor cells and stromal cells creating a unique expression signature that promotes osteolytic breast cancer bone metastasis and that inhibition of such interactions can be developed as targeted therapeutics.
  • Microarray analysis was performed to investigate gene expression profiling at the tumor-bone (TB) interface versus the tumor alone area from syngenic mice injected with three different syngenic mammary tumor cell lines that differ in their metastatic potential.
  • Knockdown of MMP13 expression at the TB interface leads to significant reduction in bone destruction and in the number of activated osteoclasts at the TB interface.
  • Further analysis to evaluate the mechanism of MMP13-dependent osteolytic bone metastasis revealed that MMP13-ASO treatment decreased active MMP9, RANKL levels, and transforming growth factor-beta signaling at the TB interface.
  • Together, our data indicate that upregulation of MMP13 at the TB interface is important in tumor-induced osteolysis and suggest that MMP13 is a potential therapeutic target for breast cancer bone metastasis.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] Am J Pathol. 1999 Feb;154(2):469-80 [10027405.001]
  • [Cites] Clin Exp Metastasis. 2009;26(7):797-808 [19590968.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 18;328(3):679-87 [15694401.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):544-54 [15551360.001]
  • [Cites] Cancer Cell. 2005 May;7(5):485-96 [15894268.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):41-9 [16407878.001]
  • [Cites] Nature. 2006 Apr 27;440(7088):1222-6 [16642001.001]
  • [Cites] Lung Cancer. 2006 Jun;52(3):349-57 [16569461.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):541-9 [17180711.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5803-11 [18632634.001]
  • [Cites] Cancer Sci. 2009 Jan;100(1):71-81 [19038005.001]
  • [Cites] Clin Exp Metastasis. 2009;26(3):205-13 [19112599.001]
  • [Cites] Cancer Lett. 2009 Apr 18;276(2):212-20 [19114293.001]
  • [Cites] J Clin Invest. 2009 Apr;119(4):837-51 [19307728.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3143-9 [19383809.001]
  • [Cites] PLoS One. 2009;4(5):e5620 [19440335.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Mol Cancer Res. 2009 Aug;7(8):1224-33 [19671689.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):163-76 [10652271.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 10;1489(1):19-30 [10806994.001]
  • [Cites] Adv Immunol. 2000;75:115-57 [10879283.001]
  • [Cites] J Cell Biol. 2000 Nov 13;151(4):879-89 [11076971.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Apr;10(2):383-92, x [11382593.001]
  • [Cites] Curr Opin Investig Drugs. 2001 Oct;2(10):1444-9 [11890363.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):25-30 [12063545.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2002;37(3):149-66 [12139441.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1318-26 [12698202.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3110-6 [15131051.001]
  • [Cites] Methods Enzymol. 1987;144:140-71 [3041177.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3059-61 [2032246.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1399-405 [1540948.001]
  • [Cites] J Cell Biochem. 1993 Dec;53(4):288-95 [8300745.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2823-6 [8187059.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] J Pathol. 1998 Oct;186(2):144-50 [9924429.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] Int J Cancer. 1996 Aug 22;69(4):350-3 [8797881.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1544-9 [8833902.001]
  • [Cites] J Bone Miner Res. 1996 May;11(5):665-70 [9157781.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):499-508 [9250162.001]
  • [Cites] EMBO J. 1997 Sep 1;16(17):5353-62 [9311995.001]
  • [Cites] Eur J Biochem. 1997 Sep 1;248(2):369-73 [9346290.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4882-8 [9354453.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1546-56 [9362421.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1588-94 [9362426.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1348-52 [9537227.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):91-101 [9665469.001]
  • [Cites] Endocr Relat Cancer. 1999 Sep;6(3):333-47 [10516850.001]
  • (PMID = 20406980.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA72781; United States / NCI NIH HHS / CA / R29 CA072781; United States / PHS HHS / / KG090860; United States / NCI NIH HHS / CA / CA072781-08; United States / NCI NIH HHS / CA / R01 CA072781-08; United States / NCI NIH HHS / CA / P30 CA036727; United States / NCI NIH HHS / BC / BC083293; None / None / / P30 CA036727-24; United States / NCI NIH HHS / CA / R01 CA072781; United States / NCI NIH HHS / CA / P30 CA036727-24; United States / NCI NIH HHS / CA / P30CA036727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / Osteoprotegerin; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / Tnfrsf11b protein, mouse; 0 / Tnfsf11 protein, mouse; 0 / Transforming Growth Factor beta; EC 3.4.24.- / Matrix Metalloproteinase 13; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS186360; NLM/ PMC2862120
  •  go-up   go-down


31. Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM: NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol; 2010 Aug;34(8):1097-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NKX3.1 as a marker of prostatic origin in metastatic tumors.
  • Although most studies have shown that staining for NKX3.1 protein is positive in the majority of primary prostatic adenocarcinomas, it has been shown to be downregulated in many high-grade prostate cancers, and completely lost in the majority of metastatic prostate cancers (eg, in 65% to 78% of lesions).
  • A recent study showed that NKX3.1 staining with a novel antibody was highly sensitive and specific for high-grade prostatic adenocarcinoma when compared with high-grade urothelial carcinoma.
  • This raised the question that this antibody may perform better than earlier used antibodies in metastatic prostate tumors.
  • However, the sensitivity and specificity for prostate carcinomas for this antibody in metastatic lesions was not determined.
  • Although prostate-specific antigen (PSA) and prostatic-specific acid phosphatase (PSAP) are excellent tissue markers of prostate cancer, at times they may be expressed at low levels, focally, or not at all in poorly differentiated primary and metastatic prostatic adenocarcinomas.
  • The purpose of this study was to determine the performance of NKX3.1 as a marker of metastatic adenocarcinoma of prostatic origin.
  • Immunohistochemical staining against NKX3.1, PSA, and PSAP was carried out on a tissue microarray (TMA) (0.6-mm tissue cores) of hormone naïve metastatic prostate adenocarcinoma specimens from lymph nodes, bone, and soft tissue.
  • To determine the specificity of NKX3.1 for prostatic adenocarcinoma, we used TMAs that contained cancers from various sites including the urinary bladder, breast, colon, salivary gland, stomach, pancreas, thyroid, and central nervous system, and standard paraffin sections of cancers from other sites including the adrenal cortex, kidney, liver, lung, and testis.
  • The sensitivity for identifying metastatic prostatic adenocarcinomas overall was 98.6% (68/69 cases positive) for NKX3.1, 94.2% (65/69 cores positive) for PSA, and 98.6% (68/69 cores positive) for PSAP.
  • NKX3.1 seems to be a highly sensitive and specific tissue marker of metastatic prostatic adenocarcinoma.
  • In the appropriate clinical setting, the addition of IHC staining for NKX3.1, along with other prostate-restricted markers, may prove to be a valuable adjunct to definitively determine prostatic origin in poorly differentiated metastatic carcinomas.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Mar;163(3):972-9 [10688034.001]
  • [Cites] Arch Pathol Lab Med. 2008 Sep;132(9):1388-96 [18788849.001]
  • [Cites] Dev Dyn. 2000 Oct;219(2):248-60 [11002344.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6111-5 [11085535.001]
  • [Cites] J Urol. 2001 Apr;165(4):1329-34 [11257711.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1495-503 [11839815.001]
  • [Cites] Urology. 2001 Jun;57(6):1179-83 [11377343.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2884-9 [11854455.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):2999-3004 [12036903.001]
  • [Cites] Prostate. 2003 May 1;55(2):111-7 [12661036.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3886-90 [12873978.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1607-14 [15111307.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):307-15 [14739905.001]
  • [Cites] Prostate. 2004 Aug 1;60(3):246-56 [15176054.001]
  • [Cites] J Urol. 2004 Sep;172(3):1134-9 [15311057.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):275-89 [15323145.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):215-27 [15368473.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3869-73 [7689419.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3273-7 [7515768.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jul;10(3):151-9 [7522037.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2959-62 [7606709.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jul;13(3):168-74 [7669736.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2411-6 [8625320.001]
  • [Cites] Urology. 1997 Oct;50(4):643-7 [9338751.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4455-9 [9377551.001]
  • [Cites] Urology. 1998 Oct;52(4):637-40 [9763084.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):81-5 [9815541.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2259-69 [9840525.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):966-77 [10215624.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1164-73 [15734999.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1059:33-40 [16382041.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):88-104 [16512601.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10683-90 [17108105.001]
  • [Cites] Histopathology. 2007 Mar;50(4):472-83 [17448023.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1246-55 [17667550.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1351-5 [17721190.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1322-6 [18670358.001]
  • [Cites] Differentiation. 2008 Jul;76(6):717-27 [18557759.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • (PMID = 20588175.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA058236-16; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA058236-16; United States / NCI NIH HHS / CA / P50 CA058236-07; United States / NCI NIH HHS / CA / P50 CA58236
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / NKX3-1 protein, human; 0 / Transcription Factors; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS272269; NLM/ PMC3072223
  •  go-up   go-down


32. Tohfe M, Baki SA, Saliba W, Ghandour F, Ashou R, Ghazal G, Bahous J, Chamseddine N: Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature. Cases J; 2008;1(1):316
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature.
  • INTRODUCTION: Prostate cancer has a high tendency to spread to bone.
  • Pulmonary metastasis and generalized lymphadenopathy commonly develop after pelvic and bone involvement have already occurred.
  • Few patients with prostate cancer present initially with symptomatic metastatic lung lesions and lymphadenopathy without any other concomitant distant dissemination.
  • A chest X-ray was done revealing multiple "cannon ball" infiltrates involving all segments of the lung parenchyma.
  • Despite the absence of any detectable osseous lesions and with the presence of multiple hilar, mediastinal, para-aortic, and pelvic lymphadenopathy, the patient had a complete work-up in search for the primary adenocarcinoma.
  • His prostate specific antigen was 146 ng/ml and a prostatic biopsy done, revealing an acinar prostatic adenocarcinoma.
  • A tru-cut biopsy of a lung lesion under computed tomography guidance showed a metastatic prostatic adenocarcinoma positive for prostate specific antigen stain.
  • CONCLUSION: This case sheds light on an unusual metastatic pattern of prostatic adenocarcinoma.
  • It also emphasizes the importance of including prostate cancer in the differential diagnosis of men with adenocarcinoma of unknown origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):216-9 [16678051.001]
  • [Cites] Urol Int. 1998 Oct;61(1):17-21 [9792977.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2706-9 [7743474.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1843-6 [2317763.001]
  • [Cites] Mil Med. 2000 Dec;165(12):973-4 [11149072.001]
  • [Cites] Radiology. 1985 Mar;154(3):601-4 [2578678.001]
  • (PMID = 19014682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2590613
  •  go-up   go-down


33. Saif MW, Galanina N, Ravage-Mass L, Kaley K, Cornfeld D, Lamb L, Chhieng D: Bone Metastasis as the Only Metastatic Site in a Patient with Pancreatic Cancer following Distal Pancreatectomy. Case Rep Med; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone Metastasis as the Only Metastatic Site in a Patient with Pancreatic Cancer following Distal Pancreatectomy.
  • Other less common sites are the lung, brain, kidney, and bone.
  • Here, we report an interesting case of pancreatic adenocarcinoma with exclusive bone metastases and discuss briefly the possible pathogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20862374.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2938458
  •  go-up   go-down


34. Yoneyama K, Yamada A, Koshida Y, Toriumi F, Murayama T, Toeda H, Imazu Y, Motegi K, Akamatsu H, Ooyama R: [A patient with pulmonary metastasis from breast cancer after surgery who responded to S-1]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thoracic CT at the end of the sixth course revealed the disappearance of the metastatic focus.
  • S-1 showed potent antitumor effects and good tolerance, and it may be useful for treating metastatic/recurrent breast cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Antimetabolites, Antineoplastic / therapeutic use. Breast Neoplasms / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Carcinoembryonic Antigen / blood. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Mastectomy, Segmental. Middle Aged. Mucin-1 / blood. Quality of Life

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637559.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 0 / Mucin-1; 0 / ST 439 antigen, human; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


35. Geller SA: Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma. J Natl Med Assoc; 2009 May;101(5):478
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Immunohistochemistry. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Female. Humans. Neoplasms, Unknown Primary / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Natl Med Assoc. 2008 Dec;100(12):1469-73 [19110917.001]
  • (PMID = 19476202.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


36. Huang H, Zhang Y, Zhao HY, Wang ZQ, Xu F, Xu GC, Zhang L, Guan ZZ: [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):148-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
  • OBJECTIVE: The aim of this study is to evaluate the efficacy and safety of Gefitinib in the treatment of Chinese patients with recurrent advanced non-small-cell lung cancer (NSCLC).
  • All patients were histologically or/and cytologically confirmed to have a locally advanced or metastatic NSCLC, and failed to previous standard treatments.
  • The results of COX model analysis suggested that the patients with adenocarcinoma, rash and favourable performance status (PS) had longer TTP.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Diarrhea / chemically induced. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Remission Induction. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538895.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


37. Ruiz M, Salvador J, Bayo J, Lomas M, Moreno A, Valero M, Bernabé R, Vicente D, Jiménez J, Lopez-Ladrón A: Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol; 2008 Nov;62(6):1085-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
  • BACKGROUND: Addition of carboplatin (C) to trastuzumab (T) and paclitaxel (P) improves the efficacy in HER2+ metastatic breast cancer (MBC).
  • RESULTS: Forty-one patients (pts) were enrolled-median age: 54.5 years (range 29-75); 87.8% PS 0 or 1; 39 (97.5%) had received prior adjuvant or neoadjuvant treatment; 11 (27%) had received one prior CT line for metastatic disease; disease sites: liver (40%), bone (32.5%), lymph nodes (32.5%) and lung (20%); 19 (47.5%) had > or =2 lesions and 97.5% had measurable disease.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Genes, erbB-2

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365200.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; BG3F62OND5 / Carboplatin; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


38. Liou MJ, Lin JD, Chung MH, Liau CT, Hsueh C: Renal metastasis from papillary thyroid microcarcinoma. Acta Otolaryngol; 2005 Apr;125(4):438-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Distant metastasis caused by thyroid microcarcinoma is uncommon, and is usually found in the lung or bone.
  • Clinically detectable well-differentiated metastatic thyroid carcinoma to the kidney is rare, and only 16 cases have been reported.
  • Herein we describe a case of metastatic papillary thyroid microcarcinoma to the kidney in a patient with a pelvic fracture and pulmonary metastasis.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Papillary / secondary. Kidney Neoplasms / secondary. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Calcinosis / diagnosis. Calcinosis / pathology. Disease Progression. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Middle Aged. Pelvic Bones / pathology. Thyroglobulin / blood. Thyroid Gland / pathology. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823819.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


39. Tazi N, Le Thi Huong D, Bodaghi B, Rixe O, Lehoang P, Piette JC: [Choroidal metastasis revealing pulmonary adenocarcinoma]. Rev Med Interne; 2006 Sep;27(9):699-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis revealing pulmonary adenocarcinoma].
  • Lung cancer is the first cause of choroidal metastasis in man.
  • He presented with visual decrease and metamorphopsia that lead to the diagnosis of a metastatic adenocarcinoma of the lung (bone, liver, choroid, nodles).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872723.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Hirose T, Tanaka J, Shimizu M: Multicentric contiguous variant of epithelioid angiosarcoma of the bone. A rare variant showing angiotropic spread. Ann Diagn Pathol; 2005 Feb;9(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric contiguous variant of epithelioid angiosarcoma of the bone. A rare variant showing angiotropic spread.
  • Epithelioid angiosarcoma of the bone is a rare tumor and is a diagnostic challenge.
  • The initial diagnosis of a tibial biopsy was poorly differentiated adenocarcinoma.
  • On the occasion of autopsy, a fungating thrombotic nodule was found at the anterior wall of the right atrium, and small hemorrhagic infarcts with tumor thrombi were found in the lung.
  • This case showed angiotropic spread of the tumor only to the right atrium and the lung, with no solid mass in other organs.
  • Multicentric epithelioid angiosarcoma of the bone is a pitfall in pathological diagnoses, especially if a strong radiological impression of metastatic carcinoma is provided.
  • [MeSH-major] Bone Neoplasms / pathology. Epithelioid Cells / pathology. Hemangiosarcoma / secondary. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Antigens, CD31 / analysis. Biomarkers, Tumor / analysis. Biopsy. Diagnosis, Differential. Fatal Outcome. Humans. Immunohistochemistry. Keratins / analysis. Male. Middle Aged. Neoplasm Invasiveness / pathology. Tibia / pathology. Vimentin / analysis. von Willebrand Factor / analysis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692948.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / Vimentin; 0 / von Willebrand Factor; 68238-35-7 / Keratins
  •  go-up   go-down


41. Ahlmann ER, Greene NW, Menendez LR, Stevanovic MV: Unusual locations for metastatic malignancy of the hand: a report of three cases. J Surg Orthop Adv; 2008;17(4):267-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual locations for metastatic malignancy of the hand: a report of three cases.
  • Metastatic tumors of the hand bones are very rare.
  • This report presents three cases of metastatic lesions involving the bones of the hand.
  • These metastases, with adenocarcinoma of the lung as the primary malignancy, were the first clinical presentation of adenocarcinoma in two of these patients.
  • The hamate bone was involved in one patient and the proximal phalanx of the ring finger was involved in the other patient.
  • The third patient developed metastatic disease to the distal phalanx 8 months after initial diagnosis.
  • The authors emphasize that a lytic lesion in the hand may be the first clinical sign of a malignancy or progression to metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / secondary. Finger Phalanges. Hamate Bone. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138500.001).
  • [ISSN] 1548-825X
  • [Journal-full-title] Journal of surgical orthopaedic advances
  • [ISO-abbreviation] J Surg Orthop Adv
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Yang L, Liu XY, Fang J, An TT, Wu MN: [Gefitinib in the treatment of advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Jun;28(6):474-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gefitinib in the treatment of advanced non-small cell lung cancer].
  • OBJECTIVE: To investigate the efficacy, time to progression, survival time and toxicity of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor Gefitinib (Iressa), a target therapy agent, in the treatment of advanced non-small cell lung cancer (NSCLC), and to analyze the factors affecting the efficacy and patients' survival.
  • The disease control rate of those who had adenocarcinoma, or received second-line chemotherapy or developed skin toxicity was significantly better than the other patients (P value = 0.04, 0.02, 0.00, respectively). (2) Median time to progress (TIP) was 5.0 months (95% CI 3.26-6.74). (3) Median following-up duration was 7.5 months (1-18.
  • Non-smoker, stable diseases, skin toxicities, and controlled metastatic diseases during the treatment of gefitinib were the favorable factors affecting the survival (P value = 0.00, 0.00, 0.00, 0.01, respectively). (4) The main toxicity of gefitinib was grade I or II skin toxicity.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Disease Progression. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome


43. Bahk WJ, Rhee SK, Kang YK, Lee AH, Park JM, Chung YG: Gastric cancer acrometastases to all digits of one hand following closed intramedullary nailing. Skeletal Radiol; 2006 Jul;35(7):529-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic malignant tumor of the hand is unusual and the most common site of the primary cancer is lung.
  • Acrometastases to the phalanges of the hand usually involve a single bone, while those proximal to the phalanges often involve multiple bones.
  • To our knowledge, only five cases have been reported in the literature to date and there has been no reported case following closed intramedullary nailing for metastatic diaphyseal fracture of an ipsilateral long bone.
  • [MeSH-major] Adenocarcinoma / complications. Bone Neoplasms / complications. Fingers / pathology. Fracture Fixation, Intramedullary. Fractures, Spontaneous / etiology. Humerus / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Metastasis. 1983 Jul-Sep;1(3):205-12 [6546199.001]
  • [Cites] J Hand Surg Br. 1988 Aug;13(3):306-7 [3171299.001]
  • [Cites] Hand Surg. 2001 Dec;6(2):239-42 [11901474.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jun;78(6):891-6 [8666607.001]
  • [Cites] Surgery. 1951 Mar;29(3):466-72 [14835133.001]
  • [Cites] Acta Cytol. 1994 Jul-Aug;38(4):589-91 [8042428.001]
  • [Cites] Hand. 1972 Oct;4(3):268-72 [5083969.001]
  • [Cites] J Bone Joint Surg Am. 1972 Dec;54(8):1665-76 [4569465.001]
  • [Cites] J Bone Joint Surg Am. 1976 Dec;58(8):1061-6 [1002745.001]
  • [Cites] J Surg Oncol. 1983 Oct;24(2):99-102 [6632902.001]
  • [Cites] J Bone Joint Surg Am. 1983 Dec;65(9):1331-5 [6654944.001]
  • [Cites] J Bone Joint Surg Am. 1986 Jun;68(5):743-6 [3459730.001]
  • [Cites] Br J Cancer. 1965 Mar;19:15-29 [14284378.001]
  • [Cites] Arch Surg. 1967 Mar;94(3):307-12 [6018878.001]
  • [Cites] Cancer. 1970 Dec;26(6):1199-203 [5483651.001]
  • [Cites] J Hand Surg Am. 1978 May;3(3):271-6 [275346.001]
  • [Cites] J Surg Oncol. 1985 Feb;28(2):146-50 [2982063.001]
  • (PMID = 16283175.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, Almhanna K, Smith D, Philip PA: A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol; 2010 Oct;21(10):1999-2004
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
  • This phase II study was undertaken to determine the effects of adding bevacizumab to a regimen of docetaxel and oxaliplatin in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction.
  • PATIENTS AND METHODS: Previously untreated patients with locally advanced or metastatic disease and a performance status (PS) of 0-1 were eligible for this study.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Lancet Oncol. 2009 Jun;10(6):559-68 [19482548.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Cancer Metastasis Rev. 1990 Nov;9(3):171-4 [1705485.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Pathol Int. 1998 Jul;48(7):499-506 [9701011.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):933-6 [9714067.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Langenbecks Arch Surg. 1999 Jun;384(3):264-70 [10437615.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Ann Oncol. 2007 Dec;18(12):2006-8 [17951596.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):104-8 [17897959.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):542-6 [18212754.001]
  • [Cites] Anticancer Drugs. 2008 Jun;19(5):535-9 [18418220.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5326-34 [18854571.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):347-53 [19066894.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • (PMID = 20332133.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-22453
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2980934
  •  go-up   go-down


45. Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M: Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene; 2006 Aug 31;25(39):5467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • About 25% of the Tg-N-ras carcinomas displayed large, poorly differentiated areas, featuring vascular invasion and forming lung, bone or liver distant metastases.
  • These findings support the notion that mutated ras oncogenes could be able to drive the formation of thyroid tumors that can progress to poorly differentiated, metastatic carcinomas.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adenoma / genetics. Adenoma / pathology. Amino Acid Substitution. Animals. Cell Differentiation. Humans. Mice. Mice, Transgenic. Neoplasm Invasiveness


46. Shelly MJ, Dheer S, Kavanagh EC: Metastatic adenocarcinoma of the lung mimicking mucoid degeneration of the anterior cruciate ligament. Ir J Med Sci; 2010 Jun;179(2):309-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the lung mimicking mucoid degeneration of the anterior cruciate ligament.
  • We report a case of a 63-year-old male with known adenocarcinoma of the lung who presented with knee pain which was initially diagnosed as mucoid degeneration of the anterior cruciate ligament (ACL) on magnetic resonance imaging (MRI).
  • Due to persistent knee pain an interval MRI was performed, followed by image guided biopsy which showed metastatic adenocarcinoma of the lung infiltrating the ACL.
  • [MeSH-major] Adenocarcinoma / pathology. Anterior Cruciate Ligament / pathology. Knee Joint / pathology. Lung Neoplasms / pathology. Mucins / analysis. Soft Tissue Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 2001 Jun;30(6):312-5 [11465770.001]
  • [Cites] Skeletal Radiol. 2004 Jun;33(6):359-62 [14997351.001]
  • [Cites] Acta Radiol. 2008 Feb;49(1):75-9 [18210315.001]
  • [Cites] J Bone Joint Surg Am. 1992 Mar;74(3):435-7 [1548272.001]
  • [Cites] J Rheumatol. 1977 Spring;4(1):65-72 [886554.001]
  • [Cites] Joint Bone Spine. 2002 Oct;69(5):495-8 [12477235.001]
  • [Cites] Arthroscopy. 1999 Jan-Feb;15(1):98-102 [10024041.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1283-7 [15100133.001]
  • [Cites] J Bone Joint Surg Br. 1999 Mar;81(2):304-5 [10204939.001]
  • (PMID = 19288177.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


47. Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP: A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol; 2007 Jan;59(1):51-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
  • PURPOSE: Treatment options in patients with recurrent non-small cell lung cancer (NSCLC) remain limited as a result of poor activity of most agents after failure of platinum-based therapy.
  • RESULTS: Forty-nine patients entered the phase I and II part of the study (phase I: 12-phase II: 37 + 3 at DL-3), and 40 patients were evaluable for a response in phase II and all for toxicity: median age, 61 years (range 36-74); PS, 1 (0-2); gender, 43 males/6 females-histologies; adenocarcinoma, 25; squamous, 20; large cell, 4.
  • Metastatic sites included lymph nodes, 38; bone, 5; liver, 4; brain, 3; lung nodules, 14; adrenals, 13; other, 3.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622691.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Bridged Compounds; 0 / Organoplatinum Compounds; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 1605-68-1 / taxane; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


48. Kocak M, Mayadagli A, Ozkan A, Parlak C, Demir O, Marti A, Dogan Eren M, Kaya S, Gumus M: Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience. J BUON; 2007 Oct-Dec;12(4):471-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience.
  • PURPOSE: Despite advances in the detection and treatment, the long-term survival of patients with advanced nonsmall cell lung cancer (NSCLC) remains poor, with a 5-year overall survival (OS) of less than 5%.
  • We conducted this observational study to determine the influence of docetaxel plus cisplatin combination chemotherapy on response, time to progression (TTP) and OS, and to evaluate its tolerability in chemotherapy-naïve patients with metastatic NSCLC.
  • PATIENTS AND METHODS: Patients with histologically or cytologically confirmed stage IV NSCLC who met the following criteria were eligible for the study: no previous chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, objectively measurable disease, adequate bone marrow reserve, normal hepatic and renal function.
  • Histological type was squamous cell carcinoma in 21 (42%) patients, adenocarcinoma in 11 (22%) and undifferentiated carcinoma in 18 (36%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067204.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


49. Katakami N: [Lung cancer with bone metastasis]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1049-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer with bone metastasis].
  • Lung cancer is one of the most common solid tumors to develop metastases to bone.
  • The prognosis of patients with metastatic lung cancer to bones is short,usually less than 6 months.
  • Radiotherapy for metastatic bone tumor is a mainstay to relieve pain and control the localized disease.
  • Prophylactic fixation for long bone fractures is recommended in cases where 30 to 50% of the cortex has been destroyed, pain is present after radiotherapy, or life expectancy is more than 3 months.
  • Systemic chemotherapy has been proved to prolong survival of patients with metastatic non-small-cell lung cancer (NSCLC) as well as extensive small cell lung cancer (SCLC).
  • Gefitinib in upfront or second-line treatment is an optional therapy in adenocarcinoma patients without a history of smoking.
  • The third generation bisphosphonate zoledronate has been demonstrated to improve cancer pain and to prevent skeletal morbidity in lung cancer patients with metastatic bone disease.
  • [MeSH-major] Analgesics / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Pain, Intractable / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carboplatin / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Diphosphonates / therapeutic use. Drug Administration Schedule. Etoposide / administration & dosage. Fractures, Bone / prevention & control. Humans. Paclitaxel / administration & dosage. Prognosis. Quinazolines / administration & dosage. Radiotherapy Dosage. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912519.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics; 0 / Diphosphonates; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


50. Fujie S, Okumura Y, Sato S, Akaki S, Katsui K, Himei K, Takemoto M, Kanazawa S: Diagnostic capabilities of I-131, TI-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy. Acta Med Okayama; 2005 Jun;59(3):99-107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic capabilities of I-131, TI-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy.
  • We defined the metastases as those cases in which serum thyroglobulin (Tg)increased significantly or in which we were able to prove the lesions on CT (computed tomography), MRI (magnetic resonance imaging) or bone scintigram.
  • The sensitivity of the mediastinum was appropriate, except for I-131 before ablation, and the sensitivity of the lung before and after ablation was inferior for either tracer.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnostic imaging. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adult. Aged. Cell Differentiation. Female. Humans. Iodine Radioisotopes. Male. Middle Aged. Postoperative Care. Radionuclide Imaging. Radiopharmaceuticals. Sensitivity and Specificity. Technetium Tc 99m Sestamibi. Thallium Radioisotopes

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049563.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Thallium Radioisotopes; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


51. Pentheroudakis G, Golfinopoulos V, Pavlidis N: Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer; 2007 Sep;43(14):2026-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Published reports on identification of CUP primary site by autopsy or microarray-based multigene expression platforms were retrieved and analysed for year of publication, primary site, patient age, gender, histology, rate of primary identification, manifestations and metastatic deposits, microarray chip technology, training and validation sets, mathematical modelling, classification accuracy and number of classifying genes.
  • RESULTS: From 1944 to 2000, a total of 884 CUP patients (66% males) underwent autopsy in 12 studies after presenting with metastatic or systemic symptoms and succumbing to their disease.
  • A primary was identified in 644 (73%) of them, mostly in the lung (27%), pancreas (24%), hepatobiliary tree (8%), kidneys (8%), bowel, genital system and stomach, as a small focus of adenocarcinoma or poorly differentiated carcinoma.
  • An unpredictable systemic dissemination was evident with high frequency of lung (46%), nodal (35%), bone (17%), brain (16%) and uncommon (18%) deposits.
  • Between the 1944-1980 and the 1980-2000 series, female representation increased, 'undetermined neoplasm' diagnosis became rarer, pancreatic primaries were found less often while colonic ones were identified more frequently.
  • Four studies using microarray technology profiled more than 500 CUP cases using classifier set of genes (ranging from 10 to 495) and reported strikingly dissimilar frequencies of assigned primary sites (lung 11.5%, pancreas 12.5%, bowel 12%, breast 15%, hepatobiliary tree 8%, kidneys 6%, genital system 9%, bladder 5%) in 75-90% of the cases.
  • Discrepant assignment of primary sites by microarrays may be due to the presence of 'sanctuary sites' in autopsies, molecular misclassification and the postulated presence of a pro-metastatic genetic signature.
  • [MeSH-major] Microarray Analysis / methods. Neoplasms, Unknown Primary / diagnosis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698346.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Frankel BM, Jones T, Wang C: Segmental polymethylmethacrylate-augmented pedicle screw fixation in patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical evaluation. Neurosurgery; 2007 Sep;61(3):531-7; discussion 537-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segmental polymethylmethacrylate-augmented pedicle screw fixation in patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical evaluation.
  • OBJECTIVE: Instrumentation of the osteoporotic spine may result in bone failure because of pedicle screw loosening and pullout.
  • A clinical evaluation of a novel fenestrated bone tap used in pedicle screw augmentation was performed to determine the performance and safety of this technique.
  • Of these patients, 23 had bone softening secondary to osteoporosis and/or metastatic spinal tumor involvement.
  • RESULTS: Six patients (26%) had metastatic spine disease (squamous cell lung carcinoma, renal cell carcinoma, bladder carcinoma, breast, prostate, and uterine adenocarcinoma); five patients (22%) had a degenerative spondylolisthesis; and 12 patients (52%) had burst fractures, eight as a result of benign causes and four as a result of metastatic disease.
  • Four (17%) patients underwent revision surgery of previous pedicle screw failure resulting from bone softening and pseudarthrosis.
  • [MeSH-major] Bone Density. Bone Screws / standards. Osteoporosis / surgery. Polymethyl Methacrylate / standards. Spinal Neoplasms / surgery


53. Ak I, Sivrikoz MC, Entok E, Vardareli E: Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Eur J Cardiothorac Surg; 2010 Apr;37(4):792-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
  • OBJECTIVE: At present, metastatic bone involvement is usually assessed using bone scintigraphy, which has a high sensitivity but a poor specificity.
  • The objective of our study was to compare the sensibility of the 2-deoxy-2-[18F] fluoro-d-glucose positron emission tomography/computed tomography (F-18 FDG PET/CT) for the detection of bone metastasis in patients with non-small-cell lung cancer (NSCLC) whose technetium 99m methylenediphosphonate (Tc-99m MDP) bone scans were absolutely normal.
  • MATERIAL AND METHODS: This study based on the retrospective analysis of 95 consecutive patients with histologically proven NSCLC who underwent F-18 FDG PET/CT and Tc-99m MDP bone scan at the Eskişehir Osmangazi University School of Medicine, Department of Nuclear Medicine between November 2006 and October 2008.
  • Nineteen patients (19 of 95, 20%) with absolutely normal Tc-99m bone scan versus multiple high-grade F-18 FDG avid bony metastases on F-18 FDG PET/CT were selected for the review.
  • RESULTS: Nine patients had squamous cell carcinoma, six had adenocarcinoma, three had large cell carcinoma and one had adenosquamous cell carcinoma.
  • Tc-99m MDP bone scan that did not reveal bony abnormalities or radiotracer uptake was characteristic of benign disease (defined as absolutely normal) in these patients.
  • Whereas, F-18 FDG PET/CT not only showed extremely disseminated heterogeneous nest-like high-grade FDG avid metastatic foci within the marrow cavity of the upper and lower thoracic spine, lumbar spine, pelvis, rib cages and bilateral proximal long bones, but also showed disseminated osteolytic bony metastases in these areas.
  • CONCLUSION: Discordant findings of skeletal metastasis between Tc-99m MDP bone scans and F-18 FDG PET/CT imaging may be seen in 20% of the patients with NSCLC.
  • F-18 FDG PET/CT could detect metastatic bone involvement more accurately than bone scintigraphy.
  • Bone scans are insensitive to early bone marrow neoplastic infiltration.
  • Assessment of glucose metabolism with FDG PET/CT can represent a more powerful tool to detect early bone metastases in lung cancer than with traditional bone scans.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20015657.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


54. Yano T, Haro A, Yoshida T, Morodomi Y, Ito K, Shikada Y, Shoji F, Maruyama R, Maehara Y: Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol; 2010 Dec 1;102(7):852-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer.
  • OBJECTIVES: In this study, we investigated prognostic factors associated with survival after distantly metastatic recurrence in surgically resected non-small cell lung cancer (NSCLC), and clarified the influence of local treatment on the prognosis for oligometastatic recurrence.
  • The targeted metastatic organs were brain in 14 patients, bone in 14, lungs in 12, and other organs in 4.
  • Significant prognostic factors for postrecurrence survival included adenocarcinoma histology, long disease-free interval (DFI) (1 year or longer), and the performance of local treatment for oligometastases.
  • [MeSH-major] Bone Neoplasms / surgery. Brain Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery


55. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS: Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer; 2005 Dec 15;104(12):2753-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
  • A Phase II trial was conducted to study a combination of oral capecitabine and gemcitabine (CapGem) as first-line therapy in patients with advanced and/or metastatic biliary carcinoma.
  • METHODS: Patients with unresectable or metastatic intrahepatic or extrahepatic biliary duct carcinoma and gallbladder carcinoma were enrolled.
  • Eligible patients had histologically or cytologically confirmed, measurable adenocarcinoma and had not received prior therapy with capecitabine or gemcitabine.
  • CONCLUSIONS: CapGem is an active and well tolerated first-line combination chemotherapy regimen for patients with advanced/metastatic biliary tract carcinoma that offers a convenient home-based therapy.
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Bone Neoplasms / secondary. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16294346.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


56. Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A: Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology; 2005 Jan;65(1):126-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
  • Patients with bone metastases also received zoledronic acid.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Alopecia / chemically induced. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Biomarkers, Tumor / blood. Combined Modality Therapy. Diphosphonates / administration & dosage. Disease Progression. Disease-Free Survival. Drug Resistance, Neoplasm. Estramustine / administration & dosage. Estramustine / adverse effects. Humans. Imidazoles / administration & dosage. Life Tables. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Proteins / blood. Neutropenia / chemically induced. Orchiectomy. Pain / drug therapy. Palliative Care. Prostate-Specific Antigen / blood. Radiotherapy, High-Energy. Remission Induction. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667877.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Diphosphonates; 0 / Imidazoles; 0 / Neoplasm Proteins; 0 / Taxoids; 15H5577CQD / docetaxel; 35LT29625A / Estramustine; 6XC1PAD3KF / zoledronic acid; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


57. Ramkumar U, Munshi NI, El-Jabbour JN: Occult carcinoma of the lung presenting as pain in the hallux: a case report. J Foot Ankle Surg; 2005 Nov-Dec;44(6):483-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult carcinoma of the lung presenting as pain in the hallux: a case report.
  • Metastatic tumors to the hands and feet (acrometastases) are rare.
  • We report a case in which the primary presentation of a lung carcinoma was a metastatic lesion to the distal phalanx of the hallux.
  • Radiographs and computed tomography suggested a benign lesion in the distal phalanx of the hallux, but curettage and biopsy revealed metastatic adenocarcinoma.
  • A chest x-ray revealed a mass in the right perihilar region, which was confirmed by CT, bronchoscopy, and biopsy as carcinoma of the lung.
  • A review of the literature reveals that there is a tendency toward delayed diagnosis in similar cases, especially when the primary lesion is asymptomatic.
  • A high index of suspicion is needed for early diagnosis in such cases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Bone Neoplasms / secondary. Hallux / pathology. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257681.001).
  • [ISSN] 1067-2516
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Sato T, Soejima K, Nakayama S, Satomi R, Sayama K, Asano K: [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung]. Nihon Kokyuki Gakkai Zasshi; 2010 Oct;48(10):765-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung].
  • A 76-year-old woman with multiple bone metastases from lung adenocarcinoma was admitted due to a pathological femoral fracture.
  • Fat embolism syndrome should be considered as a differential diagnosis if consciousness disturbance and respiratory failure occur in patients with metastatic bone carcinoma and pathological long bone fractures.
  • [MeSH-major] Adenocarcinoma / complications. Embolism, Fat / etiology. Femoral Fractures / etiology. Fractures, Spontaneous / etiology. Lung Neoplasms / complications
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Female. Humans

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066866.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


59. VanWye WR: Patient screening by a physical therapist for nonmusculoskeletal hip pain. Phys Ther; 2009 Mar;89(3):248-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hip pain is a common complaint addressed by physical therapists; therefore, it would be advantageous for them to be knowledgeable about differential diagnosis for hip pain, so that they can screen for possible serious conditions outside the realm of physical therapist practice and make the appropriate referral.
  • OUTCOMES: The patient was diagnosed later with primary lung adenocarcinoma with widespread metastases.
  • A computerized tomography scan of the left hip revealed a metastatic lesion at the left proximal femur.
  • DISCUSSION: Physical therapists' ability to adequately screen for conditions requiring examination by a physician can lead to a more timely diagnosis of serious medical conditions.
  • [MeSH-major] Arthralgia / etiology. Bone Neoplasms / complications. Hip Joint. Lung Neoplasms / complications. Physical Therapy Modalities. Referral and Consultation
  • [MeSH-minor] Aged. Humans. Male. Osteoarthritis / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168712.001).
  • [ISSN] 1538-6724
  • [Journal-full-title] Physical therapy
  • [ISO-abbreviation] Phys Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Zhang JQ, Huang XQ, Zhang J, Cai P, Chen W, Wang J, Zhou DQ, Zhang EQ: [CT guided radioactive seed (125)I implantation in treating multiple bone metastasis]. Zhonghua Yi Xue Za Zhi; 2008 Oct 28;88(39):2739-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CT guided radioactive seed (125)I implantation in treating multiple bone metastasis].
  • OBJECTIVE: To investigate the clinical value of CT guided radioactive seed (125)I implantation in treating bone metastasis.
  • METHODS: 28 multiple bone metastatic tumor patients with 116 metastatic lesions totally, adenocarcinoma of lung in 6 cases, squamous cell carcinoma of lung, renal clear-cell carcinoma, and carcinoma of prostate in 4 cases each, hepatocellular carcinoma and colon carcinoma in 3 cases each, breast carcinoma in 2 cases, and malignant schwannoma and pancreatic cancer in 1 case each, 13 males and 15 females, aged 49.8, underwent CT guided radioactive seed (125)I implantation into bone metastatic lesions.
  • CONCLUSION: CT guided radioactive seed (125)I implantation procedure has good clinical effects in treating bone metastasis with minimal invasive and few complications.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Brachytherapy / methods. Iodine Radioisotopes / therapeutic use

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080445.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


61. Segawa N, Abe H, Nishida T, Katsuoka Y: [A case of prostatic cancer discovered from lung metastatic lesions]. Hinyokika Kiyo; 2006 Feb;52(2):147-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of prostatic cancer discovered from lung metastatic lesions].
  • We report a case in a 70-year-old patient indicated to have a metastatic lesion from a chest X-ray taken during a medical examination.
  • Transrectal sextant needle biopsy of the prostate was performed, revealing moderately differentiated adenocarcinoma.
  • Computed tomography (CT) scan and bone scintigraphy showed intrapelvic lymphnode adenopathy and metastasis to the right pubic bone.
  • Under a diagnosis of stage D2 prostate cancer, we initiated endocrine therapy (luteinizing hormone-releasing hormone analogue depot every 4 weeks and bicalutamide).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Agents, Hormonal / administration & dosage. Lung Neoplasms / secondary. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology


62. Thöm I, Schult-Kronefeld O, Burkholder I, Schuch G, Andritzky B, Kastendieck H, Edler L, Wagener C, Bokemeyer C, Schumacher U, Laack E: Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases. Anticancer Res; 2009 Jan;29(1):249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, CEACAM-1 is not expressed in normal lung tissue or melanocytes.
  • It has been demonstrated that an expression in these tissues is associated with the development of metastatic disease.
  • The aim of the present investigation was to analyze a possible association between the expression of CEACAM-1 in pulmonary adenocarcinomas and their lymph node and hematogenous metastatic cells.
  • PATIENTS AND METHODS: CEACAM-1 expression was immunhistochemically evaluated in primary tumors, lymph nodes and distant metastases of 96 patients with metastatic pulmonary adenocarcinoma who had undergone surgery between 1999 and 2002.
  • This investigation demonstrates that its expression is preserved in lymph node and hematogenous metastases, indicating that its expression is of functional significance for both metastatic sites.
  • These results support the prognostic relevance of the expression of CEACAM-1 in pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / secondary. Antigens, CD / biosynthesis. Cell Adhesion Molecules / biosynthesis. Lung Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331157.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules
  •  go-up   go-down


63. William WN Jr, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES: Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol; 2010 Apr;33(2):148-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
  • OBJECTIVES: Combination chemotherapy with third-generation, nonplatinum agents (ie, gemcitabine, vinorelbine, taxanes, or camptothecins) represents a well-tolerated frontline treatment option for metastatic non-small-cell lung cancer and might play a role as salvage therapy as well.
  • The aim of this phase 2 study was to investigate the use of docetaxel and vinorelbine in the frontline and second-line setting in patients with incurable non-small-cell lung cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687727.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


64. Gontier E, Vaylet F, Bonardel G, Mantzarides M, Salles Y, Guigay J, Foehrenbach H, L'Her P: [18-FDG positon emission tomography and distal metastasis from lung cancer]. Rev Pneumol Clin; 2005 Sep;61(4 Pt 1):248-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18-FDG positon emission tomography and distal metastasis from lung cancer].
  • We report the cases of three patients with non-small-cell lung cancer who developed secondary distal localizations beyond the acquisition field of "whole body" FDG-PET.
  • Lung cancer is known to favor hematogenic dissemination, raising the possibility of early distal metastasis.
  • Furthermore, the diagnostic yield of this type of examination may be low since it can be estimated that about 1% of patients will develop isolated distal metastases (3 out of 293 patients in our series initially treated for non-metastatic non-small-cell lung cancer).
  • In the current context of technical availability, systematic inclusion of the lower limbs in the PET scan acquisition field would not appear warranted for the initial work-up of patients with non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Fluorodeoxyglucose F18. Lung Neoplasms / pathology. Positron-Emission Tomography. Radiopharmaceuticals. Whole Body Imaging
  • [MeSH-minor] Adenocarcinoma / secondary. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Female. Femur / pathology. Humans. Male. Middle Aged. Muscle Neoplasms / secondary. Retrospective Studies. Tibia / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208188.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


65. Spiteri V, Bibra A, Ashwood N, Cobb J: Managing acrometastases treatment strategy with a case illustration. Ann R Coll Surg Engl; 2008 Oct;90(7):W8-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Frequently, these lesions present in a similar way to benign conditions leading to erroneous diagnosis and inappropriate treatment.
  • When located in the finger, the most frequent cause is lung cancer, while in the toes it is due to genito-urinary tumours.
  • Awareness of the possibility of metastatic disease during orthopaedic assessment is essential to decrease patient morbidity.
  • A case that was referred to our institution with a single metastasis in a digit from occult gastric adenocarcinoma is used to illustrate the way these lesions are managed.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Fingers. Skin Neoplasms / secondary. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hand Surg Am. 1999 Nov;24(6):1245-8 [10584948.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1964 Jan;91:155-60 [14113760.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2002 Nov-Dec;57(6):283-6 [12612761.001]
  • [Cites] Dermatol Surg. 2003 Mar;29(3):294-6 [12614427.001]
  • [Cites] Clin Orthop Relat Res. 2003 Apr;(409):223-31 [12671506.001]
  • [Cites] J Hand Surg Br. 2003 Dec;28(6):578-81 [14599832.001]
  • [Cites] Cancer. 1976 Mar;37(3):1492-95 [1260668.001]
  • [Cites] JAMA. 1977 Jun 20;237(25):2746-7 [577230.001]
  • [Cites] Clin Orthop Relat Res. 1982 Oct;(170):219-25 [7127951.001]
  • [Cites] J Bone Joint Surg Am. 1983 Dec;65(9):1331-5 [6654944.001]
  • [Cites] J Bone Joint Surg Am. 1986 Jun;68(5):743-6 [3459730.001]
  • [Cites] J Am Acad Dermatol. 1994 Aug;31(2 Pt 1):259-63 [8040412.001]
  • [Cites] Acta Cytol. 1994 Jul-Aug;38(4):589-91 [8042428.001]
  • [Cites] Br J Dermatol. 1999 Apr;140(4):776-7 [10233355.001]
  • [Cites] Nucl Med Commun. 2001 Aug;22(8):875-9 [11473206.001]
  • (PMID = 18831862.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2728313
  •  go-up   go-down


66. Yang S, Dong Q, Yao M, Shi M, Ye J, Zhao L, Su J, Gu W, Xie W, Wang K, Du Y, Li Y, Huang Y: Establishment of an experimental human lung adenocarcinoma cell line SPC-A-1BM with high bone metastases potency by (99m)Tc-MDP bone scintigraphy. Nucl Med Biol; 2009 Apr;36(3):313-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of an experimental human lung adenocarcinoma cell line SPC-A-1BM with high bone metastases potency by (99m)Tc-MDP bone scintigraphy.
  • BACKGROUND: Bone metastasis is one of the most common clinical phenomena of late stage lung cancer.
  • A major impediment to understanding the pathogenesis of bone metastasis has been the lack of an appropriate animal and cell model.
  • This study aims to establish human lung adenocarcinoma cell line with highly bone metastases potency with (99m)Tc-MDP bone scintigraphy.
  • METHODS: The human lung adenocarcinoma cancer cells SPC-A-1 were injected into the left cardiac ventricle of NIH-Beige-Nude-XID (NIH-BNX) immunodeficient mice.
  • The metastatic lesions of tumor-bearing mice were imaged with (99m)Tc-MDP bone scintigraphy on a Siemens multi-single photon emission computed tomography.
  • The mice with bone metastasis were sacrificed under deep anesthesia, and the lesions were resected.
  • Bone metastatic cancer cells in the resected lesions were subjected for culture and then reinoculated into the NIH-BNX mice through left cardiac ventricle.
  • RESULTS: The bone metastasis sites were successfully revealed by bone scintigraphy.
  • The established bone metastasis cell line SPC-A-1BM had a high potential to metastasize in bone, including mandible, humerus, thoracic vertebra, lumbar, femur, patella, ilium and cartilage rib.
  • Gene expression difference was found between parental and bone-seeking metastasis cell SPC-A-1BM, which indicates SPC-A-1BM has metastatic capacity vs. its parental cells.
  • CONCLUSION: SPC-A-1BM is a bone-seeking metastasis human lung adenocarcinoma cell line.
  • Bone scintigraphy may be used as an accurate, sensitive, noninvasive tool to detect experimental bone metastases in intact live NIH-BNX mice.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Bone and Bones / radionuclide imaging. Lung Neoplasms / pathology. Technetium Tc 99m Medronate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324277.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


67. Choi HR, Lee PB, Kim KH: Scapuloplasty alleviates scapular pain resulting from lung cancer metastasis. Pain Physician; 2010 Sep-Oct;13(5):485-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scapuloplasty alleviates scapular pain resulting from lung cancer metastasis.
  • Osteoplasty, a highly effective minimally invasive procedure that alleviates the painful effects of metastatic bone disease by injecting bone cement to support weakened bones, provides immediate and substantial pain relief.
  • According to the reported incidences of operative treatment of different scapula fracture types, 99% of all isolated scapula body fractures are treated nonoperatively A 54-year-old man had been experiencing metastatic bone pain in the lateral border, medial border, and medial infraspinatus fossa of the left scapula for the past 2 months; this pain originated from adenocarcinoma of the right lung.
  • Three 13-gauge, 10-cm long bone biopsy needles were simultaneously inserted from the 3 different entry points to fill the osteolytic lesion with the bone cement with fluoroscopic guidance under local anesthesia and intravenous analgesia.
  • Scapuloplasty is a new variant of osteoplasty used to alleviate the painful effects of metastatic bone disease.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Cements / therapeutic use. Bone Neoplasms / secondary. Lung Neoplasms / pathology. Orthopedic Procedures / methods. Scapula / surgery
  • [MeSH-minor] Fractures, Bone / surgery. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20859318.001).
  • [ISSN] 2150-1149
  • [Journal-full-title] Pain physician
  • [ISO-abbreviation] Pain Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Cements
  •  go-up   go-down


68. Duda DG, Cohen KS, Kozin SV, Perentes JY, Fukumura D, Scadden DT, Jain RK: Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood; 2006 Apr 1;107(7):2774-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors.
  • Recent studies have demonstrated that the cellular contribution of the bone marrow to tumor neovascularization is highly complex.
  • In this context, the extent to which bone marrow-derived cells incorporate as bona fide endothelial (nonhematopoietic) cells into perfused tumor vessels, or any new vessels formed postnatally (vasculogenesis), is unclear.
  • To this end, we developed models to characterize local vessel-derived and bone marrow-derived endothelial cells (BMD-ECs).
  • Finally, we quantified their contribution to perfused blood vessels in tumors using transplanted as well as spontaneous primary and metastatic tumor models.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Jan;105(1):17-9 [10619857.001]
  • [Cites] Nat Cell Biol. 2005 Sep;7(9):870-9 [16113679.001]
  • [Cites] Cell. 2001 May 4;105(3):369-77 [11348593.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Nat Med. 2002 Jun;8(6):607-12 [12042812.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Nat Med. 2003 Jun;9(6):789-95 [12740570.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):515-6 [12842078.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):277-89 [14585355.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):763-8 [14718670.001]
  • [Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1769-77 [15187022.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5920-4 [15342367.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2084-6 [15191949.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Nat Med. 1999 Apr;5(4):434-8 [10202935.001]
  • [Cites] Blood. 2005 Jan 15;105(2):679-81 [15358628.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):101-11 [15652753.001]
  • [Cites] Nat Med. 2005 Mar;11(3):261-2 [15723071.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):113-21 [15784169.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • (PMID = 16339405.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01-CA80124; United States / NCI NIH HHS / CA / R01-CA115767; United States / NCI NIH HHS / CA / R01-CA96915
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ PMC1895376
  •  go-up   go-down


69. Nakamura H, Kuirhara Y, Matsushita K, Sakai A, Yamaguchi T, Nakajima Y: Extrarenal multiorgan metastases of collecting duct carcinoma of the kidney: a case series. J Med Case Rep; 2008;2:304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These lesions were biopsied, resulting in a histological diagnosis of metastatic adenocarcinoma.
  • Autopsy demonstrated the primary tumor to be collecting duct carcinoma, with metastases to lung, liver, spleen, bone marrow, right adrenal gland, and para-aortic lymph node.
  • Computed tomography done while the patient was alive detected lung, liver, and para-aortic lymph node metastases.
  • Autopsy revealed a primary tumor of collecting duct carcinoma with metastases to the liver, right adrenal gland, right upper ureter, bone marrow, para-aortic and mediastinal lymph nodes, and bone.
  • CONCLUSION: We present the radiological findings of lung, liver, lymph node, and bone metastases in two patients with collecting duct carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1986 Nov;10(11):1131-41 [3542784.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):449-56 [2318486.001]
  • [Cites] J Urol. 2003 Apr;169(4):1287-90 [12629344.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):627-33 [11222193.001]
  • [Cites] Histopathology. 1991 Feb;18(2):115-22 [1707029.001]
  • [Cites] J Urol. 2000 Apr;163(4):1090-5; quiz 1295 [10737472.001]
  • [Cites] Eur J Radiol. 2006 Mar;57(3):453-60 [16266796.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):54-67 [9503506.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):399-403 [8626899.001]
  • [Cites] Arch Esp Urol. 2000 Sep;53(7):611-6 [11037654.001]
  • (PMID = 18798981.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556681
  •  go-up   go-down


70. Tamura M, Dohhba S, Funaki K, Sasaki S, Michiwa Y, Kurosaka Y, Takekawa S, Kiriyama M, Kojima Y, Kita T: [Pulmonary pleomorphic carcinoma; report of 2 cases]. Kyobu Geka; 2006 Jul;59(7):585-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy of the bone revealed metastatic adenocarcinoma.
  • With a diagnosis of primary lung cancer (cT2N1M1), two-staged operation was performed.
  • Pathological diagnosis was pleomorphic carcinoma [pT2N1M1 (OSS), stage IV].
  • Chest CT revealed a tumor in the right hilar region, which was diagnosed as adenocarcinoma by transbronchial lung biopsy.
  • Autopsy revealed pleomorphic carcinoma of the lung with metastasis to the brain, costa and mediastinal lymph nodes.
  • [MeSH-major] Adenocarcinoma / radiography. Carcinoma / radiography. Lung Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856536.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Ozcanli H, Ozdemir H, Ozenci AM, Söyüncü Y, Aydin AT: [Metastatic tumors of the hand in three cases]. Acta Orthop Traumatol Turc; 2005;39(5):445-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic tumors of the hand in three cases].
  • Metastatic malignancies of the hand are rare and they usually develop from lung, breast, and kidney tumors.
  • We presented three patients with metastatic tumors of the hand, whose ages were 58 (male), 42 (female), and 40 (male) years.
  • Metastases developed in the thumb and the big toe, metacarpal bone, and the nail bed following treatment for primary tumors of the bladder, colon, and chondrosarcoma of the proximal femur, respectively.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bone Neoplasms / diagnosis. Hand
  • [MeSH-minor] Adult. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531705.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 25
  •  go-up   go-down


72. Pillai P, Mendel E, Ray-Chaudhury A, Slone W, Ammirati M, Chiocca AE: Metastasis development at the site of cervical spine arthrodesis. Acta Neurochir (Wien); 2010 Mar;152(3):509-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biologically, the site of arthrodesis provides a microenvironment replete of growth factors and active remodeling, which is propitious for bone regrowth.
  • There is a theoretical possibility though that this microenvironment would also provide a fertile site for metastatic deposits to occur.
  • We present the clinical, radiographic, and pathological features of a case of previously undiagnosed metastatic adenocarcinoma, occurring 1 year following anterior arthrodesis and fusion for cervical spondylotic myelopathy at the C3-C4 level.
  • [MeSH-major] Adenocarcinoma / secondary. Arthrodesis / adverse effects. Lung Neoplasms / pathology. Spinal Fusion / adverse effects. Spinal Neoplasms / secondary. Spondylosis / surgery
  • [MeSH-minor] Bone Regeneration / physiology. Cervical Vertebrae / pathology. Cervical Vertebrae / radiography. Cervical Vertebrae / surgery. Chemotaxis / physiology. Decompression, Surgical. Disease Progression. Diskectomy / adverse effects. Fatal Outcome. Humans. Intercellular Signaling Peptides and Proteins / metabolism. Intercellular Signaling Peptides and Proteins / secretion. Intervertebral Disc Displacement / pathology. Intervertebral Disc Displacement / radiography. Intervertebral Disc Displacement / surgery. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Neoplasm Metastasis / prevention & control. Neurosurgical Procedures. Osteogenesis / physiology. Reoperation. Spinal Cord Compression / pathology. Spinal Cord Compression / radiography. Spinal Cord Compression / surgery. Spinal Stenosis / pathology. Spinal Stenosis / radiography. Spinal Stenosis / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19551339.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


73. Laganà D, Carrafiello G, Mangini M, Lumia D, Mocciardini L, Chini C, Pinotti G, Cuffari S, Fugazzola C: Hepatic radiofrequency under CT-fluoroscopy guidance. Radiol Med; 2008 Feb;113(1):87-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 14 lesions comprised seven residual tumours after combined embolisation and US-guided RFA of a large hepatocellular carcinoma (HCC), which were indistinguishable from necrosis or surrounding healthy parenchyma; two HCC nodules in locations that were inaccessible by US; five metastases (two from renal carcinoma, two from colorectal adenocarcinoma and one from lung carcinoma), of which one could not be distinguished from the surrounding healthy parenchyma on US and four were inaccessible by US.
  • In 2/3 metastatic lesions with portal vein supply, there were no recurrences at 3 and 6 months; in 1/3, we observed disease progression, with the appearance of additional nodules at 6 months.
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma / secondary. Carcinoma / surgery. Carcinoma, Hepatocellular / surgery. Carcinoma, Hepatocellular / therapy. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Colonic Neoplasms / pathology. Disease Progression. Disease-Free Survival. Embolization, Therapeutic. Female. Follow-Up Studies. Humans. Image Processing, Computer-Assisted / methods. Kidney Neoplasms / pathology. Lung Neoplasms / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Sep;232(3):381-91 [10973388.001]
  • [Cites] Radiology. 2001 Jul;220(1):161-7 [11425990.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2006 Apr;16(2):112-6 [16773015.001]
  • [Cites] AJR Am J Roentgenol. 1995 Aug;165(2):329-32 [7618549.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1253-8 [11044017.001]
  • [Cites] Cardiovasc Intervent Radiol. 2005 Jul-Aug;28(4):481-4 [16001134.001]
  • [Cites] Urology. 2001 May;57(5):976-80 [11337311.001]
  • [Cites] J Bone Joint Surg Am. 1998 Jun;80(6):815-21 [9655099.001]
  • [Cites] Radiology. 2000 Jul;216(1):9-10 [10887221.001]
  • [Cites] Radiology. 2001 Jul;220(1):145-9 [11425987.001]
  • [Cites] Radiology. 2003 Feb;226(2):441-51 [12563138.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):2102-6 [10950066.001]
  • [Cites] Surg Endosc. 2006 Aug;20(8):1262-7 [16858532.001]
  • [Cites] Eur J Radiol. 2007 Feb;61(2):351-5 [17097255.001]
  • [Cites] Radiol Med. 2003 Sep;106(3):201-12 [14612841.001]
  • [Cites] J Vasc Interv Radiol. 2001 Dec;12(12):1417-21 [11742017.001]
  • [Cites] Radiology. 1999 Sep;212(3):673-81 [10478231.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Clin Nucl Med. 2003 Mar;28(3):192-7 [12592125.001]
  • [Cites] Cardiovasc Intervent Radiol. 2005 Sep-Oct;28(5):589-94 [16132384.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1619-25 [11090390.001]
  • [Cites] J Vasc Interv Radiol. 2002 Nov;13(11):1155-61 [12427816.001]
  • [Cites] Radiology. 2000 Dec;217(3):633-46 [11110923.001]
  • [Cites] Arch Intern Med. 1995 Jan 23;155(2):137-47 [7811123.001]
  • [Cites] AJR Am J Roentgenol. 2002 Feb;178(2):359-61 [11804892.001]
  • [Cites] Radiology. 2002 Apr;223(1):255-62 [11930075.001]
  • [Cites] Clin J Pain. 1996 Dec;12(4):311-5 [8969876.001]
  • [Cites] Eur J Radiol. 2004 Jun;51 Suppl:S19-23 [15311434.001]
  • [Cites] J Vasc Interv Radiol. 2001 Oct;12 (10 ):1135-48 [11585879.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12 (4):608-11 [16489676.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jan;174(1):57-9 [10628454.001]
  • [Cites] Radiographics. 2001 Oct;21 Spec No:S17-35; discussion S36-9 [11598245.001]
  • [Cites] J Vasc Interv Radiol. 2001 Sep;12(9):1021-32 [11535764.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):705-11 [10954454.001]
  • [Cites] Abdom Imaging. 2000 Jan-Feb;25(1):81-5 [10652928.001]
  • [Cites] Am J Med. 1996 Mar;100(3):344-56 [8629682.001]
  • [Cites] J Clin Ultrasound. 1999 Jun;27(5):221-9 [10355885.001]
  • [Cites] Radiology. 1999 Mar;210(3):655-61 [10207464.001]
  • [Cites] Br J Radiol. 2001 Nov;74(887):983-6 [11709461.001]
  • [Cites] Radiology. 2000 Jul;216(1):180-4 [10887246.001]
  • [Cites] J Vasc Interv Radiol. 2005 Jul;16(7):981-90 [16002506.001]
  • [Cites] Magn Reson Med. 1999 Jul;42(1):141-9 [10398960.001]
  • (PMID = 18338130.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


74. Lee DK, Park JH, Kim JH, Lee SJ, Jo MK, Gil MC, Song KH, Park JW: Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. Korean J Urol; 2010 May;51(5):358-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The whole-body workup revealed multiple metastases to the lymph nodes, bone, liver, and lung.
  • He underwent laminectomy, posterior fixation, and epidural mass excision, and metastatic adenocarcinoma from the prostate was diagnosed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Clin Oncol. 2007 Dec;12(6):427-32 [18071861.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):198-204 [17171704.001]
  • [Cites] J Urol. 1995 Dec;154(6):2128-31 [7500474.001]
  • [Cites] Urology. 2000 Sep 1;56(3):527-32 [10962338.001]
  • [Cites] Int J Urol. 2001 Jul;8(7):374-9 [11442659.001]
  • [Cites] Eur Urol. 2000 Sep;38(3):250-4 [10940696.001]
  • [Cites] Int Urol Nephrol. 2003;35(2):189-92 [15072491.001]
  • (PMID = 20495701.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2873892
  • [Keywords] NOTNLM ; Disease progression / Multiple organ failure / Neoplasm metastasis / Prostate-specific antigen / Prostatic neoplasms
  •  go-up   go-down


75. Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Fedeli SL, Giordani P, Casadei V, Baldelli AM, Graziano F, Catalano G: Weekly paclitaxel in elderly patients (aged &gt; or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer; 2008 Sep;9(5):280-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
  • PURPOSE: Paclitaxel and platinum-based chemotherapy is considered to be a standard approach for locally advanced and metastatic non-small-cell lung cancer (NSCLC).
  • The aim of our study was to investigate the activity and safety of weekly paclitaxel in elderly patients with locally advanced (stage IIIB) and metastatic (stage IV) NSCLC.
  • CONCLUSION: Our study confirmed that paclitaxel 80 mg/m2 weekly is active in patients with locally advanced and metastatic NSCLC with a good safety profile; this schedule might be considered an alternative choice to gemcitabine or vinorelbine as first-line treatment in elderly patients, particularly patients with comorbidities.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma / drug therapy. Carcinoma / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Prognosis. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824450.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


76. Inaoka T, Takahashi K, Aburano T, Miyokawa N, Tandai S, Kobayashi T, Matsuno T: Spinal metastasis from lung cancer fifteen years after surgery presenting a pseudohemangioma appearance of the vertebra: a case report. Spine (Phila Pa 1976); 2010 Feb 1;35(3):E86-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal metastasis from lung cancer fifteen years after surgery presenting a pseudohemangioma appearance of the vertebra: a case report.
  • OBJECTIVE: To describe a case of solitary metastasis of the seventh thoracic vertebra (T7) from lung cancer 15 years after surgery.
  • SUMMARY OF BACKGROUND DATA: Late recurrence of the bone over 5 years after curative surgery for lung cancer is highly exceptional.
  • In addition, bone metastasis from lung cancer showing a coarse trabecular pattern of the vertebra on computed tomography (CT) is quite unusual.
  • METHODS: A case of solitary metastasis of T7 from lung cancer 15 years after surgery showing a pseudohemangioma appearance of the vertebra on CT is presented.
  • He had undergone a left lower lobectomy for lung cancer 15 years previously.
  • No other lesion was detected by whole-body CT and bone scintigraphy.
  • Tumor resection and T5-T9 posterior spinal fusion had been performed, and a pathologic diagnosis of metastatic pulmonary adenocarcinoma of the bone was established.
  • CONCLUSION: We have reported a rare case of solitary metastasis to T7 appearing 15 years after surgery for lung cancer.
  • The incidence of lung cancer recurrence more than 5 years after surgery is exceedingly low; however, even in patients with lung cancer, late occurrence of bone metastasis should be considered and included in the differential diagnosis of a pseudohemangioma appearance of the vertebra.
  • [MeSH-major] Hemangioma / radiography. Lung Neoplasms / radiography. Spinal Neoplasms / radiography. Spinal Neoplasms / secondary. Thoracic Vertebrae / radiography
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075786.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Zhong XJ, Li DT, Li XL, Mu DB, Zhang XG, Luo JY: [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]. Ai Zheng; 2007 Jul;26(7):785-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas].
  • Although bronchioloalveolar carcinoma is a subtype of lung adenocarcinoma, its biological features are better than those of other lung adenocarcinomas.
  • This study was to analyze differences in metastatic activity between bronchioloalveolar carcinoma and other lung adenocarcinomas.
  • METHODS: The expression of E-Cadherin, Collagen IV, vascular endothelial growth factor receptor-2 (VEGFR-2), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in 28 specimens of stage I bronchioloalveolar carcinoma confirmed pathologically and 40 specimens of other stage I lung adenocarcinomas were detected by immunohistochemistry.
  • RESULTS: The 5-year survival rate was significantly higher in ths patients with bronchioloalveolar carcinoma than in the patients with other lung adenocarcinomas (88.7% vs. 57.3%, P < 0.05).
  • The intrathoracic recurrence rate was significantly higher and the extrathoracic metastasis rate was significantly lower in the patients with bronchioloalveolar carcinoma than in the patients with other lung adenocarcinomas (75% vs. 33.3%, 25% vs. 66.7%, P < 0.05).
  • The positive rates of Collagen IV, E-Cadherin and TIMP-1 were significantly higher in bronchioloalveolar carcinoma than in other lung adenocarcinomas (78.6% vs. 42.5%, 78.6% vs. 40.0%, 67.5% vs. 42.9%, all P < 0.01).
  • The positive rate of VEGFR-2 was significantly higher in other lung adenocarcinomas than in bronchioloalveolar carcinoma (85.7% vs. 77.5%, P < 0.05).
  • There was no significant difference in the positive rate of MMP-9 between bronchioloalveolar carcinoma and other lung adenocarcinomas (85.0% vs. 78.6%, P = 0.494).
  • CONCLUSION: As compared with other lung adenocarcinomas, stage I bronchioloalveolar carcinoma is less aggressive in clinical behavior and likely to develop intrathoracic recurrence, with less extrathoracic metastases and better prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Collagen Type IV / metabolism. Lung Neoplasms / pathology. Neoplasm Recurrence, Local
  • [MeSH-minor] Bone Neoplasms / secondary. Brain Neoplasms / secondary. Cadherins / metabolism. Female. Follow-Up Studies. Humans. Male. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoplasm Staging. Survival Rate. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626761.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Collagen Type IV; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


78. Tirabosco R, Lang-Lazdunski L, Diss TC, Amary MF, Rodriguez-Justo M, Landau D, Lorenzi W, Flanagan AM: Clear cell sarcoma of the mediastinum. Ann Diagn Pathol; 2009 Jun;13(3):197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At thoracotomy, the mass was found tightly adherent to the esophageal wall and right lower lobe of the lung.
  • The diagnosis of clear cell sarcoma was supported by demonstrating the presence of an EWS gene rearrangement by fluorescence in situ hybridization.
  • There was no evidence that this lesion represented metastatic disease.
  • We present the case and discuss the differential diagnosis.
  • [MeSH-minor] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Diagnosis, Differential. Female. Gastrointestinal Stromal Tumors / pathology. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433300.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA-Binding Protein EWS
  •  go-up   go-down


79. Anoop TM, George S, Divya KP, Jabbar PK: Metastatic phalangeal osteolysis as an initial presentation of carcinoma colon. Am J Surg; 2010 Nov;200(5):e61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic phalangeal osteolysis as an initial presentation of carcinoma colon.
  • Metastatic malignancies of the hand are rare and usually develop from lung, breast, or kidney tumors.
  • The authors report a case of differentiated adenocarcinoma of the colon in a 76-year-old man who presented with distal phalangeal metastasis and osteolysis in the form of a painful swelling at the tip of the right little finger of 6 months duration.
  • Diagnosis was confirmed by biopsy.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Colonic Neoplasms / pathology. Finger Phalanges. Osteolysis / etiology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20870210.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Bergmann I, Weiss M, Schaffner T: [Pulmonary microscopic tumor embolism syndrome]. Dtsch Med Wochenschr; 2006 Mar 24;131(12):618-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INVESTIGATIONS: Investigations revealed an adenocarcinoma of the colon with retroperitoneal, mediastinal and supraclavicular lymph node metastasis and poorly differentiated carcinoma of the prostate with extensive bone metastases.
  • DIAGNOSIS, TREATMENT AND COURSE: During the following days the patients condition deteriorated further and both patients' died from irreversible right heart failure.
  • Both autopsies showed extensive metastatic adenocarcinoma with marked angiosis carcinomatosa of the lungs with numerous occlusions of small arteries and arterioles and resulting cor pulmonale.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Lung Neoplasms / secondary. Neoplastic Cells, Circulating / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Echocardiography. Fatal Outcome. Female. Humans. Hypertension, Pulmonary / diagnosis. Hypertension, Pulmonary / etiology. Hypertension, Pulmonary / pathology. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Pulmonary Embolism / diagnosis. Pulmonary Heart Disease / etiology. Syndrome

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16544237.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Yamamoto N, Kinoshita H, Inoue T, Kawakita S, Oguchi N, Muguruma K, Kawa G, Sakaguchi Y, Adachi Y, Sakaida N, Uemura Y, Matsuda T: [Small cell carcinoma of the prostate: a case report]. Hinyokika Kiyo; 2007 Sep;53(9):665-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 76-year-old man had been treated with maximum androgen blockade therapy for a poorly-differentiated prostate adenocarcinoma (T3cN1M0, prostate specific antigen (PSA) 65 ng/ml, Gleason Score 4+5=9) since September 2002.
  • At that time, no metastasis was detected by computed tomography and bone scintigraphy.
  • In August 2005, multiple bone metastases were detected.
  • Immunohistochemical examination of a biopsy specimen from the bone lesion revealed a small cell carcinoma/neuroendocrine cell carcinoma.
  • The autopsy showed multiple organ metastases including bone, liver, lungs and others.
  • The immunohistochemical examination revealed pure small cell carcinoma in all metastatic lesions.
  • A precise histological examination of the lungs using a 1 cm serial section could not reveal any tumors compatible with primary lung cancer.
  • We concluded from the clinical history and autopsy findings that his initial poorly-differentiated adenocarcinoma of the prostate dedifferentiated into a pure small cell carcinoma with neuroendocrine differentiation.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Cell Transformation, Neoplastic. Humans. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933147.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


82. Recchia F, Candeloro G, Necozione S, Bratta M, Bisegna R, Rea S: Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. Am J Clin Oncol; 2008 Aug;31(4):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
  • BACKGROUND: To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Camptothecin / administration & dosage. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Leucovorin / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845989.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


83. Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus NH, Nieva J, Kuhn P: Case study of the morphologic variation of circulating tumor cells. Hum Pathol; 2007 Mar;38(3):514-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a detailed cytomorphologic evaluation of the circulating component of widely metastatic breast carcinoma.
  • Wide local excision revealed a 1.7-cm infiltrating ductal adenocarcinoma, BSR score 7/9 with angiolymphatic invasion, and 4/20 lymph nodes positive for carcinoma.
  • Five years later, a bone marrow biopsy revealed involvement of bone marrow by metastatic breast carcinoma, and shortly thereafter, metastases were identified in the liver and lung hilum.
  • In addition, in comparison with her tumor cells in other sites, the full morphologic spectrum of cancer cells present in primary and metastatic tumor is also present in peripheral blood circulation.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Neoplastic Cells, Circulating / pathology


84. Pouessel D, Thezenas S, Culine S, Becht C, Senesse P, Ychou M: Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol; 2005 Dec;29(12):1224-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Hepatic metastases are often present at diagnosis of carcinoma of unknown primary site (CUP).
  • METHODS: One hundred and eighteen patients were treated at the Cancer Center of Montpellier from 1993 to 2002 for CUP initially metastatic to the liver.
  • RESULTS: The most frequent histological types observed were adenocarcinoma, undifferentiated, neuroendocrine and squamous-cell carcinomas.
  • Other metastatic sites involved lymph nodes, lung and bone.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518276.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


85. Chiesa MD, Buti S, Tomasello G, Negri F, Buononato M, Brunelli A, Lazzarelli S, Brighenti M, Donati G, Passalacqua R: A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer. Tumori; 2007 May-Jun;93(3):244-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.
  • AIMS AND BACKGROUND: Previous phase II studies have reported that combinations of oxaliplatin, folinic acid and 5-fluorouracil or irinotecan, folinic acid and 5-fluorouracil are associated with good efficacy and an acceptable safety profile in metastatic gastric cancer.
  • The aim of this study was to evaluate chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI regimen) in metastatic gastric cancer.
  • RESULTS: Seventeen patients with metastatic gastric cancer were enrolled.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Gastrointestinal Diseases / chemically induced. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neutropenia / chemically induced. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Pilot Projects. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679458.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


86. Gong Y, Ren L, Zhou L, Zhu J, Huang M, Zhou X, Wang J, Lu Y, Hou M, Wei Y: Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemother Pharmacol; 2009 Jul;64(2):327-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
  • PURPOSE: To evaluate the efficiency and toxicities of nedaplatin and paclitaxel in patients with metastatic carcinoma of the esophagus.
  • METHODS: Thirty-nine untreated patients with confirmed metastatic tumors were enrolled.
  • CONCLUSION: Comparing to other regimens, combination of nedaplatin and paclitaxel achieved an encouraging clinical outcome, with relatively minimal toxicities for patients with metastatic esophageal carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Follow-Up Studies. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048253.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


87. Shibakuki R, Seto T, Uematsu K, Shimizu K, Seki N, Nakano M, Ishii H, Ohta M, Eguchi K: Pulmonary adenocarcinoma associated with SAPHO syndrome difficult to differentiate from multiple bone metastasis. Intern Med; 2006;45(8):543-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenocarcinoma associated with SAPHO syndrome difficult to differentiate from multiple bone metastasis.
  • The patient was a 57-year-old man with a chief complaint of anterior chest pain who was diagnosed with clinical stage IV (c-T2N2M1) non-small-cell lung cancer (adenocarcinoma).
  • Bone scintigraphy showed tracer accumulation in the costal cartilage, sternoclavicular joint, and cervical vertebrae 6-7.
  • Although the bone lesions of SAPHO syndrome were difficult to differentiate from bone metastasis of pulmonary adenocarcinoma, metastatic bone tumors were ruled out by magnetic resonance imaging, computed tomography, and fluorodeoxyglucose positron emission tomography.
  • There have been no previously reported cases of lung cancer with comorbid SAPHO syndrome.
  • We report such a case and discuss the relevant literature, particularly that concerned with the evaluation of bone lesions.
  • [MeSH-major] Acquired Hyperostosis Syndrome / complications. Adenocarcinoma / complications. Adenocarcinoma / secondary. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Lung Neoplasms / complications
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - SAPHO syndrome.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702748.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


88. Wong CS, Cheung MT, Ma BB, Pun Hui E, Chan AC, Chan CK, Lee KC, Cheuk W, Lam MY, Wong MC, Chan CM, Chan JK, Chan AT: Isolated tumor cells and circulating CK20 mRNA in pN0 colorectal cancer patients. Int J Surg Pathol; 2008 Apr;16(2):119-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Follow-up of the patients for 12 months indicated that 4 patients (7%) had CRC metastases to liver, lung, and bone.
  • Long-term follow-up is necessary to study their prognostic use in patients with non-metastatic CRC.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Neoplastic Cells, Circulating / metabolism. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387990.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


89. Cardenas MG, Kini S, Wisgerhof M: Two patients with highly aggressive macrofollicular variant of papillary thyroid carcinoma. Thyroid; 2009 Apr;19(4):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report two patients with highly aggressive MFV-PTC including bone metastases, one of whom died of their disease.
  • There were multiple bone lesions on computed tomography.
  • The second patient was an 81-year-old man with a history of right thyroid nodule treated by total thyroidectomy with a postoperative diagnosis of adenomatous goiter.
  • The patient developed new bone and lung metastases.
  • He died of metastatic thyroid cancer.
  • CONCLUSIONS: To our knowledge these are the first cases of MFV-PTC reported with bone metastasis.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Bone Neoplasms / secondary. Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Fatal Outcome. Female. Humans. Male. Middle Aged. Thyroid Nodule / diagnosis. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19355832.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Tartarone A: Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature. Future Oncol; 2010 Dec;6(12):1937-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature.
  • To date, there is no standard treatment for patients with metastatic non-small-cell lung cancer after multiple previous lines of chemotherapy.
  • Pemetrexed in combination with cisplatin or as a single agent demonstrated significant activity in patients with nonsquamous non-small-cell lung cancer with a good toxicity profile.
  • In this article, we present a case of pulmonary adenocarcinoma treated with pemetrexed after five lines of treatment, including the cytotoxic agents cisplatin plus vinorelbine, docetaxel, gemcitabine and the tyrosine kinase inhibitor erlotinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives
  • [MeSH-minor] Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Combined Modality Therapy. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Pemetrexed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21142866.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


91. Parlea L, Fahim L, Munoz D, Hanna A, Anderson J, Cusimano M, Kovacs K, Gardiner G: Follicular carcinoma of the thyroid with aggressive metastatic behavior in a pregnant woman: report of a case and review of the literature. Hormones (Athens); 2006 Oct-Dec;5(4):295-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular carcinoma of the thyroid with aggressive metastatic behavior in a pregnant woman: report of a case and review of the literature.
  • We report the clinical and pathological features of a 33-year old pregnant patient with follicular carcinoma of the thyroid who presented with widespread bone and lung metastases at the time of diagnosis. the resected tumor had a focal insular component that showed extensive vascular invasion spreading beyond the thyroid capsule, and was associated with widespread bone and lung metastases.
  • We suggest that architectural differentiation of the tumor and cell proliferation rate are not reliable markers of metastatic behavior in this particular thyroid neoplasm.
  • Microvascular density and down-regulation of E-cadherin expression in the tumor should be included among histologic hallmarks of metastatic potential. the role of pregnancy in the aggressive behavior of this tumor is discussed along with a literature review.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Bone Neoplasms / secondary. Lung Neoplasms / secondary. Pregnancy Complications, Neoplastic / pathology. Thyroid Neoplasms / pathology


92. Krupitskaya Y, Eslamy HK, Nguyen DD, Kumar A, Wakelee HA: Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. J Thorac Oncol; 2009 Mar;4(3):429-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy.
  • Positron emission tomography (PET) is used routinely to follow therapeutic response in patients treated for non-small cell lung cancer (NSCLC).
  • In other disease entities though, isolated cases have been documented of asynchronous increases in activity in metastatic bone lesions ("bone flare") despite evidence of therapeutic response or stability in other lesions.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biopsy, Needle. Female. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Osteoblasts / pathology. Positron-Emission Tomography / methods. Risk Assessment. Treatment Outcome


93. Mego M, Sycova-Mila Z, Martanovic P, Liskova S, Obertova J, Mardiak J: Inflammatory skin metastasis as a first sign of progression of lung cancer--a case report. Klin Onkol; 2010;23(6):449-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory skin metastasis as a first sign of progression of lung cancer--a case report.
  • ICM in lung cancer are extremely rare and often misdiagnosed.
  • PATIENTS AND METHODS: We report on a 55-year-old man with metastatic lung adenocarcinoma and bone metastases in the axial skeleton and left humerus diagnosed in August 2008.
  • A diagnosis of skin infection was made and he was treated by antibiotic therapy without improvement.
  • RESULTS: Skin biopsy revealed skin infiltration by poorly differentiated carcinoma compatible with a primary lung tumour.
  • CONCLUSION: Metastasis of lung carcinoma could be one of the causes of inflammatory skin lesions in cancer patients and these metastases should be considered in cancer patients with persisting cutaneous lesions with signs of inflammation and no response to antibiotic therapy.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Bone Neoplasms / secondary. Humans. Male. Middle Aged. Skin / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21348413.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


94. Baur M, van Oosterom AT, Diéras V, Tubiana-Hulin M, Coombes RC, Hatschek T, Murawsky M, Klink-Alakl M, Hudec M, Dittrich C: A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. J Cancer Res Clin Oncol; 2008 Feb;134(2):125-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.
  • The efficacy and tolerability of docetaxel 100 mg/m(2) every 3 weeks as second-line chemotherapy in patients with metastatic breast cancer was investigated.
  • In conclusion, docetaxel represents one of the most active agents for second-line treatment of metastatic breast cancer, especially for anthracycline-resistant patients.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adolescent. Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Cohort Studies. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1997;39(6):557-60 [9118471.001]
  • [Cites] Eur J Cancer. 1999 Aug;35(8):1194-201 [10615229.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2341-54 [10561296.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):165-71 [8777173.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):650-6 [8761385.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1210-5 [12439707.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2879-85 [8523050.001]
  • [Cites] Breast Cancer Res. 2004;6(5):R601-7 [15318941.001]
  • [Cites] Oncology. 2001;60(1):60-5 [11150910.001]
  • [Cites] N Engl J Med. 2005 Jun 2;352(22):2302-13 [15930421.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3149-55 [9294478.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1169-77 [15718313.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):121-9 [12532428.001]
  • [Cites] Breast Cancer. 2005;12(1):11-5 [15657517.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):562-73 [10653871.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 13):S13-11-S13-18 [9335512.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2587-93 [15226326.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4165-74 [14559892.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):205-10 [10093690.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):58-65 [8558221.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):422-31 [15659489.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4927-30 [15256465.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3936-45 [11099323.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):610-1 [8103352.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):968-75 [12637459.001]
  • [Cites] J Cancer Res Clin Oncol. 1987;113(5):488-94 [3624302.001]
  • [Cites] Eur J Cancer. 1995;31A Suppl 4:S11-3 [7577098.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(3):253-8 [10453728.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2812-23 [12065558.001]
  • [Cites] Br J Clin Pharmacol. 1997 Jun;43(6):653-8 [9205828.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):529-34 [10682660.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1393-8 [11762809.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1413-24 [10334526.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):336-42 [11208824.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3 Suppl 8):21-6 [10403470.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2992-7 [12912947.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):433-40 [12598350.001]
  • (PMID = 17636328.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


95. Lange T, Müller-Tidow C, Serve H, Hoffknecht P, Berdel WE, Thomas M: First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. Oncol Rep; 2005 Dec;14(6):1539-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
  • Lung cancer has a high mortality rate and is often diagnosed in locally advanced or metastatic stages.
  • A new therapeutic option for patients with non-small cell lung cancer (NSCLC) in these stages with progress or relapse after platinum-based chemotherapy exists in the inhibitors of the epidermal growth factor receptor (EGFR) tyrosine-kinase.
  • We present a case of a 53-year-old woman who was diagnosed due to pain from multiple bone metastases of a lung adenocarcinoma.
  • She refused cytotoxic chemotherapy, and we administered first-line systemic treatment with gefitinib subsequent to radiotherapy of metastatic bone disease.
  • EGFR tyrosine-kinase inhibitors (TKI) can be an alternative first-line systemic treatment option for selected patients with metastatic NSCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Base Sequence. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. DNA Mutational Analysis. Female. Humans. Middle Aged. Neoplasm Staging. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Sequence Deletion. Treatment Outcome


96. Maeda T, Kozakai N, Nishiyama T, Ishii T, Sugiura H, Nakamura K: [Gastric metastasis from renal cell carcinoma 20 months after radical nephrectomy: a case report]. Hinyokika Kiyo; 2009 Mar;55(3):137-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic lesions from renal cell carcinoma (RCC) commonly occur in the lung and bone, gastric metastasis has rarely been reported in the literature.
  • Endoscopic needle biopsy revealed poorly differentiated adenocarcinoma.
  • Partial gastrectomy was performed and histologic examination of the resected specimen confirmed diagnosis of clear cell renal carcinoma.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378824.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


97. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ: Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer; 2005 Jul;5(2):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing patterns of bone and brain metastases in patients with colorectal cancer.
  • BACKGROUND: Therapeutic advances for patients with metastatic colorectal cancer (CRC) have been associated with prolonged survival.
  • This study was undertaken to test the hypothesis that expanded treatment options and resultant improved survival for patients with metastatic CRC are associated with an increased incidence of metastases at uncommon sites.
  • PATIENTS AND METHODS: Patients with metastatic CRC evaluated from 1993 to 2002 at the Fox Chase Cancer Center were identified.
  • Medical records were abstracted to obtain the following: date of diagnosis/metastasis, primary tumor site, therapeutic agents received, survival, and site(s) of metastases.
  • Incidence of bone and brain metastases were 10.4% (95% CI, 8.6%-12.4%) and 3% (95% CI, 2.2%-4.5%), respectively.
  • Bone metastases were more common with increased numbers of active systemic agents received: 0 (3.7%), 1 (9.4%), 2 (10.9%), 3 (16.3%), and 4/5 (17.4%; P = 0.001; trend test).
  • Patients receiving irinotecan or oxaliplatin were more likely to develop bone metastases (13.2% vs. 8.3%, P = 0.01 for irinotecan; 16.9% vs. 9%, P = 0.003 for oxaliplatin).
  • Patients with primary rectal versus primary colon cancer were more likely to develop bone metastases (16% vs. 8.6%; P = 0.001).
  • Patients with lung metastases were more likely to have bone metastases (16.1% vs. 6.4%; P < 0.0001) or brain metastases (6.2% vs. 1.2%; P < 0.0001) than those without.
  • CONCLUSION: These data demonstrate that the incidence of bone and brain metastases in patients with CRC is more common than previously reported and is associated with receipt of multiple systemic treatments.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Bone Neoplasms / epidemiology. Bone Neoplasms / secondary. Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Colorectal Neoplasms / pathology


98. Sánchez-Jiménez J, Acebal-Blanco F, Arévalo-Arévalo RE, Molina-Martínez M: Metastatic tumours in upper maxillary bone of esophageal adenocarcinoma. A case report. Med Oral Patol Oral Cir Bucal; 2005 May-Jul;10(3):252-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumours in upper maxillary bone of esophageal adenocarcinoma. A case report.
  • Primary tumours which metastasize to mouth are most commonly: lung, breast and kidney.
  • Here we present a clinical case of a patient diagnosed with esophagus adenocarcinoma which presented metastasis in upper-left maxillary bone.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Maxillary Neoplasms / secondary. Maxillary Sinus Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876970.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


99. Sakai T, Kimura D, Hatanaka R, Yamada Y, Tsushima T, Fukuda I, Kamata Y: [Surgical treated pulmonary metastasis from prostatic cancer; report of a case]. Kyobu Geka; 2010 Apr;63(4):340-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography showed solitary tumor in the lower lobe of the left lung.
  • Transbronchial lung biopsy revealed pulmonary metastasis form prostatic cancer.
  • Because no other metastatic lesions were detected, the patient underwent surgery for pulmonary lesion.
  • The wedge resection of the left lung was performed.
  • Microscopically, the diagnosis of pulmonary and multiple pleural metastases was established.
  • The pulmonary metastasis without bone nor lymph node metastasis is rare.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / secondary. Pleural Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387512.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


100. Blesa JM, Pulido EG: Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient. Anticancer Drugs; 2010 Jan;21 Suppl 1:S23-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was diagnosed with a rectum-sigma adenocarcinoma (pT1N0M0 stage).
  • Due to the development of subsequent recurrences (infravesical relapse, bone and lung progression) associated with CEA progression and pain worsening, the patient received treatment by every available agent for the metastatic colorectal cancer, including oxaliplatin and radiotherapy; irinotecan; FOLFOX schema; oral capecitabine; raltitrexed; irinotecan and cetuximab; cetuximab as a single agent; always in combination with zolendronic acid-based treatment for pain control.
  • On account of the nonmeasurable disease nature of the metastatic presentation in the present case, the clinical benefit was measured in terms of reduction of painkiller intake, improvement in performance status of the patient, and CEA serum levels.
  • In addition to all of these clinical and biological data, CT images showed an increase in necrotic area of the bone lesion without any decrease in tumor size by classical RECIST criteria.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Indoles / therapeutic use. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110784.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down






Advertisement